annual report roche group annual report group accounts roche holding ltd basel annual accounts key figures millions chf figures reported figures reported financial statements adjusted basisa change change sales ebitdab operating profit net income research development additions property plant equipment personnel number employees december ratios ebitda sales operating profit sales net income sales research development sales data shares nonvoting equity securities chfc earnings per share nonvoting equity security diluted dividend per share nonvoting equity securityd adjusted figures used internal management roche group represent results groups underlying ongoing operations exclude special items include continuing businesses seepages full description reconciliation b ebitda earnings interest financial income tax depreciation amortisation including impairment corresponds operating profit depreciation amortisation including impairment c number shares per share information restated share split took place may see note financial statements dividend proposed board directorsgroup performance glance latot latot latot latot latot sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased group figures net income millions chf net income per share ebitda millions chf nonvoting equity security chf operating profit millions chf research development millions chf additions property plant equipment millions chf figures adjusted basis figures fully comparable dueto givaudan spinoff vitamins fine chemicals demerger genentech transactions accounting policy changes per share information restated share split took place may roche group annual report group accounts roche holding ltd basel annual accounts table contents letter chairman board directors executive committee corporate governance group strategy divisions pharmaceuticals diagnostics vitamins fine chemicals people environment human resources safety environmental protection social involvement finance financial review consolidated financial statements notes consolidated financial statements report group auditors multiyear overview roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors roche global market presence subsidiaries associated companies table contents roche employee development top priority groups modern conference centre roche forum buonas switzerland provides right pleasant yet profes sional setting training development activitiesthe sale vitamins fine chemicals division legal settlements us direct customers vitamin case impairment financial assets result significant onetime charges substantial consolidated net loss pharmaceuticals diagnostics divisions grow faster global market sales core group businesses local currencies swiss francs doubledigit rise operating profit another increase margins strong cash flow solid balance sheet quantum leap forward japan result chugai alliance pegasys approved worldwide hepatitis c pharmaceuticals pipeline substantially strengthened diagnostics business expands global market lead doubledigit sales growth stable operating profit margin expected results adjusted basisletter chairman two different sets developments major impact groups financial results one hand core pharmaceuticals diagnostics divisions per formed stronglyposting abovemarket growth rates increases profitabilitygross cash flow reached new record highon othervigorous action address significant unresolved issues past resulted groups reporting substantial net lossroches financial condition nevertheless remains solidat annual general meeting board directors propose divi dend increased swiss francs per share nonvoting equity security genussschein letter chairmanwhile continuing successful revise accounting policy expansion ofour pharmaceuticals recognise impairment losses diagnostics businesseswe also made financial assets ifthe assetsmarket one ofour primary objectives value remains least address number ofunresolved original cost period ofmore issues relating vitamins six monthsas result ofthis fine chemicals divisionongoing decisionaccumulated unrealised litigation impact ofthe stock investment losses totalling market situation financial assetslast year able resolve continuing successful many ofthese challengesgiving us theflexibility room manoeuvre expansion operating businesses need strengthen company also made one primary inthe long termhoweversome themeasures adopted involved taking objectives address number substantial onetime charges unresolved issues relating financial statements provisions recorded vitamins division ongoing litigation announced last autumn settling litigationprimarily us cus impact stock market tomersin vitamin case situation financial assets last increased million million swiss francswe believe year able resolve many amount cover outstanding challenges claims direct indirect cus tomers theunited states merger ofnippon roche million swiss francs ofthe end chugai resulted net gain charged income offset impairment painful onetime impact charge connection sale measure isit gives us flexi ofthe vitamins divisionthe net bility allocate resources effect ofthese two transactions needed strate loss million swiss francs gic development ofour operating large equity holdings businesses earned significant returns roche involve risks first halfof recorded making felt todays provision million swiss francs turbulent market environmentas respect ofa longstanding lawsuit result ofstock market developments involving genentechin june past two yearsthe carrying california superior court jury awarded value ofour equity portfoliowhich city ofhope medical center mil consists primarily ofswiss smi lion us dollars additional royalties securitieshas declined sharplyin punitive damages genentechs line anticipated change alleged breach ofan agreement signed international financial reporting city ofhope standardswe decided last year roche acquired interest letter chairman genentechgenentech appealed ogypegasys received marketing jurys verdict damages award approval european union united statespegasys com reasonsroche recorded bined copegusroches propri consolidated net loss mil etary ribavirin productis currently lion swiss francs despite hepatitis c treatment groups strong operating performance highest response ratefuzeonour novel antihiv medicinemarks even corrective action milestone fight rocheremains solidly financedwith aidsas search aratio ofequity total assets cure goes onmarketing applica earning power ofthe groups tions product corebusinesses reflected another granted fasttrack review status year ofstrong gross cash flow us european authorities whichin reached record high anticipate positive decisions billion swiss francs filings first quarter decisive importance roches future acquisition ofa major ity interest chugai catapulted outlook fact achieved roche number number five japanafter overwhelming operational goals significantly majority ofchugai shareholders strengthened core pharmaceuticals approved merger oftheir company nippon roche end diagnostics businesses june antitrust authorities cleared transactionchugai ofdecisive importance roches became member ofthe roche future outlook fact group october thanks achieved operational goals neorecormon roche significantly strengthened epogin chugaiwe control core pharmaceuticals diagnos global marketing rights epo tics businesses etin betaa major anemia treatment worldwide sales ofroche prescrip outside united statesthe tion medicines increased smooth seamless integration local currencieswell ahead ofthe chugai japan ofgreat global market average importance future growth almost billion swiss francsthis pharmaceuticals businesswe growth driven mainly fourthlargest sales strong oncology portfoliowhich organisation market roches last year surpassed fivebillion established future products markwith additional boost worlds secondlargest pharma coming integration ceuticals marketchugai chugaiwe thus extended draw one ofthe biggest develop leadership key anticancer ment organisations country marketwe also significantly help consolidate strengthened presence virol roches global number two position letter chairmanin biotechnologyat beginning towards mediumterm goal new chugai started ofachieving operating profit restructuring manufacturing margin pharmaceuticals research organisations aim approaches diagnostics ofeliminating duplication cap divisions operating profit margin turing additional synergiesby also improved againfrom end chugai aims achieve thus track reach operating profit margin mediumterm target based japanese gaap increased ebitda another successful year marginthe informative roches diagnostics divisionwhich benchmark comparing compa recorded doubledigit growth fur niesprofitabilitythe margin ther extending lead com diagnostics petitors outpacing global pharmaceuticals invitro diagnostics market high industry standards substantial marginsales rd pipelines ofour two core business area ofthe businesses solid basis divisions geographic regions grew future growthin substan ahead ofthe marketas result tially expanded pharmaceuticals weare way becoming pipeline advancing pro market leader japantooin jects signing new february move aimed licensing agreements part ofour strengthening lead diabetes targeted business development carewe made tender offer activitiesthe number ofpotential acquire swiss medical device new medicines phase ii develop supplier disetronicthe worlds ment risen significantly since secondbiggest maker ofinsulin medium pumpspioneering development large projectsroche diagnostics efforts roche diagnostics also boasts broadest rd pipeline helping secure leadership posi inthe industry tion division dynamic market tools trans positive operating performance late clinical data actionable result ofour strategy offocusing health information core competency serving especially pleased highvalue healthcare market continued increase profitability margins show steady im would also like take opportu provement return sales nity express appreciation prescription medicinesthis employeesto whose skillhard work driven largely sales ofroche commitment good results prescription drugswhich last year mainly due generated operating profit mar gin ofin genentechs although economic conditions operating profit margin increased remained difficult vita nine percentage points mins fine chemicals division thus moving steadily maintained market lead andthanks letter chairman substantial volume gainsposted two main factors modest sales increase local curren declinethe appreciable fall finan ciesfollowing announcement last cial incometo million swiss spring ofour intention divest francswas due primarily lower vitamins fine chemicals divi gains equity investments sionand careful review ofthe result ofnegative developments optionswe sold division world financial marketsagainst netherlandsbased dsm group backgroundthe favourable terms beginning ofas industry onwhich roche sold final tranche buyerdsm offers complete familiarity oflabcorp shares deserves special divisions businesses mention facilitate comparisons early year novartis announced years annual report increased holding presents groups results roche nearly onethird ofthe vot consolidated adjusted basis ing sharesthe roche board ofdirec principles employed compiling tors executive committee con adjusted figureswhich exclude vinced continuing companys onetime special items represent independent course provides solid continuing operationshave basis sustainablelongterm value remained unchanged since growthmaintaining roches clear adetailed explanation ofthese prin strategic direction developing ciples found businesses continue create value stakeholders patients employees shareholders remains demerging vitamins fine top priority chemicals division acquiring major demerging vitamins fine ity stake chugai roche chemicals division acquiring strengthened focus innovative majority stake chugairoche strengthened focus pharmaceuticals diagnostics busi pharmaceuticals diagnostics synergies generatethe nesses result ideally positioned combination ofthese two innovative pursue opportunities tomorrows hightech businesses means areideally positioned pursue oppor healthcare market tunities tomorrows healthcare market excluding special itemsnet income totalled billion swiss francsa expect see positive decline previous year growth diagnostics marked drop net financial income pharmaceuticals contributing higher tax chargewhich reflects doubledigit increases sales fact operating income operating profit local currencies accounts higher proportion expect operating profit total income past margin group whole letter chairmanremain stablegiven volatility financial stock marketsit impossible present predict level offinancial income measures roche initiated give group greater financial flexibility improved operating results consolidated global leadership oncology invitro diagnostics stronger rd pipeline confirmation following right strategy improved operating resultscon solidated global leadership oncology invitro diagnostics stronger rd pipeline confirmation following right strategy past years steadily strengthened group combining organic growth complementary strategic moves forged strong position healthcare sectorwe intend maintain independent course thanks profitability ofits oper ating activities solid financial position substantial liquid reservesroche strategic flexi bility needs continue growing businesses franz bhumer letter chairman board directors executive committee corporate governance roche committed highest board succeed andres fleuen berger committees chairman standards good corporate governance horst teltschik appointed acts commitment operating finance investment committee compliance law companys andres fleuenberger henri articles incorporation swiss bmeier informed board step members code best practice corporate theannual general meeting governance promulgated swiss fritz gerber indicated time ago business association economiesuisse thatfor reasons ofagehe would stand reelection board franz b humer chairman board directors ceo ofdirectors annual general meeting board directors annual general meeting andreas oeri walter frey american economist deanne announced stand julius german political scien reelection board tist horst teltschik elected new current terms end members ofthe board ofdirectors deannejulius appointed organisational structure board audit corporate board directors governance committee andeffective roches board ofdirectors organ december named ised ensure groups board directors executive committee corporate governanceboard directors peter brabeckletmathe january left franz b humer walter frey rolf hnggi andres f leuenberger horst teltschik deanne julius andr hoffmann henri b meier andreas oeri fritz gerber john bell name year birth term ends election board directors dr franz b humer e chairman dr andres f leuenberger vicechairman rolf hnggi c vicechairman dr hc fritz gerber honorary chairman prof dr john bell c peter brabeckletmathe walter frey b andr hoffmann c dr deanne julius b dr henri b meier dr andreas oeri b dr horst teltschik secretary board directors dr gottlieb keller compliance officer finance investment committee b audit corporate governance committee c remuneration committee nonexecutive member e executive member january board directors executive committee corporate governance businesses conducted responsibly option entitles holder pur focus longterm value chase one roche nonvoting equity creationsome years ago board security genussschein price directors ofroche holding ltd swiss francs options adopted bylaws define man nontradable must exercised date fully designed later february guide board exercise ofits dutiesunder bylaws various previous years corporate officers duties delegated four commit awarded tradablelisted stock teesthe presidium ofthe board options holding period ofthree directorsnomination committee yearsas december theaudit corporate governance members ofthe executive committee committeethe finance invest held nonexercisable stock options ment committee remunera listed footnotebelow tion committeethe bylaws ofthe board ofdirectorscontaining details december nonexec internal structure ofthe board utive members ofthe board ofdirec allocation ofauthority respon tors held nonexercisable sibilitiesthe mandates ofthe board rogup options committees oversight con trol instruments available board special threeyear equity plan dealings corporate manage performance share plan mentcan found internet developed members oftop management whose performance remuneration amajor impact roches ability members ofthe board ofdirec tors receive annual remuneration wwwrochecom company corporate swiss francs serving governance httpwwwrochecomhome companycomgovintrohtm boardthe remuneration paid options tradable fair value using chairman ofthe board service blackscholes formula deducting capacity deducted average twoyear holding period agreed salarymembers serving would roughly swiss francs board committees receive additional rogis options securities identifi cation number exercise price compensation swiss francs swiss francs exercise ratio expiry time expenses date april holding period ends april market price december eight members ofthe swiss francs original issue price executive committee received fixed swiss francs taxable value recipient swiss francs salaries totalling swiss rogup options securities iden francsvariable bonuses totalling tification number exercise price swiss francs total swiss francs exercise ratio stock optionsonethird nonvoting equity securities plus one registered options subject holding givaudan share expiry date february holding period ends january market period ofone yearonethird price december swiss francs holding period oftwo yearsand one original issue price swiss francs third holding period ofthree years taxable value recipient swiss francs board directors executive committee corporate governanceexecutive committee january william burns richard laube jonathan kc knowles markus altwegg franz b humer erich hunziker heino von prondzynski daniel villiger name year birth position executive committee dr franz b humer chief executive officer dr erich hunziker chief financial officer controlling william burns pharmaceuticals division heino von prondzynski diagnostics division dr markus altwegg vitamins fine chemicals division richard laube roche consumer health prof dr jonathan kc knowles research dr daniel villiger corporate services secretary pierre jaccoud executive committee statutory auditors ernst young ltd since roche holding ltd principal auditorsjrg zrcher since conrad lffel since group auditors pricewaterhousecoopers agsince principal auditorwilliam kirst since january board directors executive committee corporate governance achieve corporate objectivesif planfuture employer contributions three years equal ofthe base salaries paid programme effectthe price executive committee members roches nonvoting equity securities outperforms average price remuneration emoluments securities issued peer set loans corporate officers companies operating one member ofthe board industryparticipating executives directors received swiss francs awarded fixed number ofnon remuneration assuming addi voting equity securitiesifroches tional duties fixed period oftime nonvoting equity securities outper otherwiseno additional remunera form securities issued ofthe tionseverance paymentsstock awards peer companiesthe board ofdirec additional fees emoluments tors elect double number werepaid tomembers ofthe board nonvoting equity securities directorsformer members ofthe awardedin event roches board ofdirectors current former nonvoting equity securities members ofthe executive committee perform average price appreciation thecompany made loans ofsecurities issued peer compa itscorporate officers niesno securities awarded programme provides possi highest total remuneration ble award nonvoting equity chairman ofthe board ceo securities members ofthe executive franz bhumer member committee board highest total remu neration received fixed equity plan open salary swiss francs roche employees roche connect variable bonus swiss members ofthe executive committee francsfor total swiss received discounts totalling francsin additionhe received swiss francs purchase ofroche nontradable optionswhich nonvoting equity securitiesnon awarded terms described voting equity securities purchased roche connect programme plan subject four franz bhumer received discount year holding period swiss francs purchase roche nonvoting equity securities none ofthe aforementioned remuner performance share plan ation stock option programmes eligible receive roche results dilution ofroche shares nonvoting equity securities ifthe ornonvoting equity securities specified performance targets achievedthe initial contribution pension plan established pension plan amounted members ofthe executive com swiss francs mittee provide coverage commensu rate salary levelsan initial shareholdings contribution swiss francs board members andr hoffmann due coverage andreas oeri fritz gerber board directors executive committee corporate governancepersons closely associated participatory rights ofshare ernst young ltd received members ofa shareholder group holders fully defined roches swiss francs services pooled voting rightsinformation articles ofincorporationas statutory auditors ofroche holding shares held group roche shares issued bearer ltd roche financial compa found notes con restrictions admis niesernst young ltd also solidated financial statementsas sion annual general meeting auditor genentechincand december members ofthe exception shares must chugai received two board persons closely associated deposited within specified companies total swiss held additional total period date ofthe meet francs auditing services sharesand ofthe ing admittance card must additional compensation datethe membersofthe executive issued shareholders nameas swiss francs services committee persons closely asso provided ofthe articles ciated held shares incorporationany shareholder may members executive elect represented another committee additional information relating shareholder annual general markus altwegghead ofthe vitamins corporate governance meetingand articles ofincor fine chemicals division since information groups poration contain restrictions member ofthe executive com corporate structure provided exercise ofvoting rightsthere mitteewill retire operational annual report section quorum requirements except role roche spring following subsidiaries associated com stipulated transfer ofthe division panies essentially identical netherlandsbased dsm groupthe major shareholders listed quorum requirements established board ofdirectors ofroche holding thenotes financial state bylaw ltd would like take opportunity ments articles ofincorporation con express deep appreciation crossholdings tain provisions manda markusaltwegg great personal information roches capital tory bid ruleswiss law applies contribution growth success structure provided annual change ofcontrol ofthe roche grouphe retain report section roche securi clausesthose components ofremu seat board ofdirectors tiesadditional details con neration based roche nonvoting fhoffmannla roche ltd tainedin roches articles ofincor equity securities would termi continue serve group porationwhich found nated event ofan acquisition capacities well wwwrochecom holding period restrictions information member preexisting awards would osamu nagayamachairman board ofdirectors execu removed ceo ofchugaiwill attend tive committee contained meetings ofthe corporate executive lists pages curricula relationship group auditors committee vitae information statutory auditors aboutboard executive com group auditorspricewaterhouse mittee members available coopers agreceived compensation wwwrochecom million swiss francs auditing servicesthey also paid million swiss francs tax consul tancy services million swiss httpwwwrochecomhomecompany francs consulting services comgovintrocomgovartihtm httpwwwrochecomhomecompany comgovintrohtm board directors executive committee corporate governance group strategy set strategic course californiabased biotech pioneer genentechthe rights pcr technol enable us sustain aboveaverage growth ogythe new gold standard rapid independent group exploiting reliable diagnostic testingsyntex corporationwhich marked entry strengths synergies core transplantation medicineand pharmaceuticals diagnostics businesses boehringer mannheimthe global market leader diagnosticsall franz b humer chairman board directors ceo transactions contributed greatly increasing value ofthe roche group terms ofour products focus expanding core healthcare pipelinetechnology base market businesses position asone presence worlds leading pharmaceutical companies global leader past five years diagnostics built longterm able step growth focusing strategyat roche began sharpen even strongly healthcare ing focus core healthcare steadily improving operating per businesses relatively early formancethe sale ofthe vitamins general industry trend fine chemicals division wasa logical strategic followon core divisions thespinoffofthe fragrances expanded series ofmajor flavours division business technology acquisitions time continued strengthen included majority interest pharmaceuticals diagnostics group strategybusinesses targeted acquisi extends fields ofproteomics another important part ofour strategy tionsimportant transactions include andgenomicsgeneticsour cross last year alone signed purchase ofavl pointofcare divisional proteomics initiativefor new agreementsalliances testing alliance exampleincludes projects develop licensing also key component chugai proposed new bloodtests early detection innovation management diag acquisition ofdisetronic insulin ofcolon breast cancer nostics divisionwhich last year pumpsannounced february acquired rights institut pas roche innovation cosmos given teurs patent portfolio pertaining two pillar strategy roche pursuing many diseases human papillomavirusto give groundbreaking strategy sets still curethe need new one exampleroche considered apart competitorswe want better treatments remains enormous partner ofchoice healthcare position group global leader research development industry pharmaceuticals diagnostics fore engine drives com focus hightech businesses panyroche pursuing innovation thanks firm focus health developing innovative solutions strategy size alone careour strong innovative core unmet medical needs whatcountswe believe pharmaceuticals diagnostics busi large organisation actually nesses extensive network ofour businesses strong slow innovation reduce productiv ofallianceswe ideally equipped successful rightbut roche ity healthcare researchso roche tomeet challenges oftodays sum ofits partswe taken different approach tomorrows healthcare market aim achieve decisive competitive one relies network ofhighly edge medium long term motivated centres ofexcellence pharmaceuticals diag collaborate closely research nostics divisions work together exchanging information technolo ever joint approach makes sound gies across geographic organisa medicalhealth economic business tional boundarieswhile maintaining senseour customers doctorslabo alarge measure ofscientific ratories patients benefit operational independence employees share holders roches pharma diagnostics research units occupy centre stage primary objective supply innovation strategywith genen medicines offering definite improve tech chugaiour two impor ments existing therapiesand tant strategic alliesalso playing topromote better clinical outcomes leading rolecomplementing also working diagnostic tests strengthening groups dynamic predict efficacytoxicity rd capabilities scientific risks ofdrug therapies individual commercial collaborations patients monitor patients biotech companies universities responses therapyour two divi innovation model also includes sions tackling joint projects roche spinoffs like bioxellset oncologydiabetesrheumatoid arthri inand biotech company tisalzheimers disease hepatitis c basilea pharmaceutica potential drug development partnerslicensing intensive collaboration agreements giving us access new pharmaceuticals diagnostics also drug candidates technologies group strategy martin passionate gardening thanks pegasys let hepatitis c interfere hobby medicine well tolerated longacting mulation taken week roche broad portfolio worldclass products hepatitis c apart pre scription medicines roferona pegasys prescribed alone combination copegus ribavirin also supply twodiagnostic tests detect measure hepatitis c virus blood samplespharmaceuticals division brief change change local millions chf chf currencies sales roche worldwide prescription group otc ebitda operating profit rd expenditures employees sales figures adjusted include reclassification sales vitamins fine chemicals division adjusted basis pharmaceuticals sales operating profitability improved significantly pharmaceuticals division oncology portfolio showed excellent sales growth leading roche prescription products five licensing agreements signed augment results oncology programmes help us expand global leadership therapeutic area long term major milestones worldwide approval pegasys treatment hepatitis cour regulatory filings hivaids drug fuzeon merger nippon roche chugai substantially strengthens position japan thanks increased rd productivity series new licensing agreements division able expand improve product portfolio year pharmaceuticals averagethis translated inswiss franc termsowing strength ofthe franc groups key trading currencieson anadjusted basisoperating profit totalled million swiss francs divisions operating profit margin increase percentage points yearearlier figurethis improvement due mainly increased sales ofroche pre scription medicines contin uedpositive impact ofrestructuring measures initiated divisional ebitda totalled million swiss francsor ofsalescompared margin prescription medicines post double digit growth worldwide salesofroche prescription medicines divisional sales excluding otc totalled million swiss francs growth local currencies well ahead ofthe global market aver one major goals leader age swiss francs onan adjusted basisoperating profit key medical areas choose serve amounted million swiss extended number francsthe operating profit margin rose furtherto one positions oncology transplanta margin previous yearebitda totalled million swiss francsor tion virology milestones ofsalescompared reached brought us major step closer achieving ambition prescription sales growth driven mainly oncology products william burns head pharmaceuticals division sales ofwhich rose bil lion swiss francsand integra tion ofchugaiother key products pharmaceuticals global market cellcept neorecormon growth surpassed sales pharmaceuticals division oncology portfolio mabtherarituxan herceptin xeloda bondronat kytril furtulon amounted million swiss neupogen neorecormon roferona francsat local currenciessales neutrogin picibanil growth ahead ofthe global market growth rates local currencies pharmaceuticalsalso posted doubledigit gains technology platforms facilitate although rocephinthe leading hospi advance research projectsscientists tal antibioticis offpatent roche chugai share informa major markets except united states tion roches leadingedge italysales ofthe product declined data management systemwhich links slightlysales erosion following groups research centres world loss ofpatent protection roaccu widethis enable companies taneaccutane less expected broaden respective capabilities generic competitors reach expertise complex field us market november ofsmall molecule development north american sales ofprescription products continued grow dou bledigit ratefuelled roches strong oncology franchisethe sharp upturn pharmaceuticals sales millions chf ofover sales japan due mainly consolidation ofchugai since october new alliance catapulted roche num ber five worlds secondlargest pharmaceutical marketsales growth europe midsingledigit rangelatin american sales affected regions macroeco nomic difficulties declined slightly less market wholesales regions showed high sin gledigit growth chugai new member roche group merger ofnippon chugais new research develop roche chugai created ment network includes fuji fifthlargest pharmaceuticals company gotemba research laboratoriesinte fourthlargest sales force gration ofthe former nippon roche japanthis provides powerful leverage research centre kamakura add existing future roche products japanese companys existing key marketmoreoverchugai strengths oncologyexpanding one ofthe biggest develop capabilities genomicsproteomics ment organisations japana factor life science technology help us develop launch another prioritythis give chugai products faster coming years solid base grow leading japanese pharmaceuticals shortly rochechugai company strong international alliance announcedthe two part drug discovery capabilities japan ners signed research agreement asian countrieseurope covering development ofcommon united states pharmaceuticals sales figures adjusted include reclassification sales vitamins fine chemicals divisionkey chugai products salesour largest fastestgrowing product generic name indication therapeutic area accounts epogin epoetin beta anemia chronic renal failure nearly one third oftotal prescription neutrogin lenograstim neutropenia associated chemotherapy drug salesthe innovative products sigmart nicorandil angina pectoris leading oncology portfolio alfarol alfacalcidol osteoporosis mabtherarituxanherceptin xelodahave market yearsand three shown extend patient survivallast year expanded strong oncology pipeline alliances com panies antisomakosan beaufour ipsen roche worldwide prescription group mabtherarituxanthe first human ised monoclonal antibody non hodgkins lymphoma nhlposted sales billion swiss francsmak ing topselling prescription medicinestudies shown product combination chop chemotherapy confers survival bene fit patients aggressive nhl inmarch mabtherarituxan received eu approval use patient populationthanks strong demand result ofthe mergerthere medicineboth indolent currently compounds devel aggressive nhlmabthera opment pipeline japan rituxan became numberone branded anticancer product chugais main therapeutic areas united states number two world oncologyrenal medicinebone wideroche actively pursuing devel joint diseasecardiovascular disease opment ofmabtherarituxan transplantation infectious thetreatment ofrheumatoid arthritis immune diseasesthe companys man interim results efficacy trial agement set itselfambitious goals published last autumn indicate end intends raise drug could provide alternative sales roughly billion yen approach managing common achieve operating profit margin disease based japanese gaap sales ofherceptina monoclonal anti oncology lead position extended body targeted therapy ofadvanced roche reinforced position breast cancerrose bil world leader oncologywith lion swiss francsall major markets groups anticancer medicines contributed increaseparticu delivering billion swiss francs larly united statesjapan pharmaceuticalswestern europein november clonal antibody specifically novel medicine awarded prix inhibits cell growth factor galienthe pharmaceutical industrys plays key role development nobel prize new blood vesselsa process known angiogenesisinterrupting process xeloda sales also strongly may way ofhalting slowing yearadvancing million tumour growth swiss francsthis oral drug breast colorectal cancer converted sales ofkytrila potent antiemetic active form tumour cellsused used control nausea vomiting combination taxoterexeloda chemotherapy patientsreturned improves survival patients growth increasing metastatic breast cancerthe product million swiss francsin august approved eu regulators product approved fda monotherapy combination ther forthe prevention treatment apy indication march postoperative nausea vomiting roche worldwide prescription group infectious disease japan others central nervous system cardiovascular disease latin america metabolic disorders inflammatory diseasebone dermatology virology sales region sales therapeutic area others transplantation north america europe anemia oncology development ofour phase iii anti marketing application bon cancer medicinestarceva avastin dronata thirdgeneration bisphos progressing plannedand phonatewas filed planned expect results ofour clinical trials europe treatment ofmetastatic available end bone disease breast cancer patients tarceva targets human epidermal decision filing expected growth factor receptor herwhich inthe fourth quarter ofrecent iscritical cell growth many trial data shown bondronat tumourstarceva currently bethe oral treatment option tested phase iii trials patients improves patientsquality oflife advanced solid tumoursinclud reduces pain effective ing nonsmall cell lung cancer intravenous bisphosphonatesbon pancreatic canceravastin mono dronat currently used manage pharmaceuticals topselling products roche worldwide prescription group change sales local product generic name indication millions chf currencies mabtherarituxan rituximab indolent nonhodgkins lymphoma rocephin ceftriaxone bacterial infections neorecormon epogin epoetin beta anemia cellcept mycophenolate mofetil transplantation herceptin trastuzumab metastatic breast cancer roaccutaneaccutane isotretinoin severe acne xenical orlistat weight loss weight control nutropin protropin somatropin somatrem growth hormone kytril granisetron chemotherapy radiation therapyinduced nausea vomiting xeloda capecitabine colorectal breast cancer dilatrend carvedilol heart failure activase tnkase alteplase tenecteplase myocardial infarction viracept nelfinavir mesylate hiv infection pulmozyme dornase alfadnase cystic fibrosis cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection furtulon doxifluridine cancer colon breast stomach lexotan bromazepam anxiety tension states madopar levodopa benserazide parkinsons disease inhibace inhibace plus cilazapril hypertension torem torasemide hypertension jointly marketed roche genentech jointly marketed roche chugai hypercalcemia abnormally elevated pean marketing application levels ofcalcium blood aonceweeklyneedlefree version cancer patients ofneorecormon patients chronic renal failurethis product anemia strenghtened presence isalso increasingly beingprescribed combined sales ofneorecormon cancer patientsthanks part andepogin rose nearly billion european approval inthe second half swiss francsa doubledigit gain ofthe year ofa onceweekly dosing neorecormon leading schedule oncological indica product anemia patients tionsin plan apply cancer renal diseaseepoginfrom approval ofneorecormon prefilled chugaiis approved use renal syringes use inanemia associated anemiain wesubmitted euro cancer pharmaceuticalstransplantation strong growth leading productin early cellcept became topselling branded product united states preventing organ rejectiontotal sales rose year nearly billion swiss francsthis medicine recognised cornerstone ofpotent lowtoxicity immunosuppressive regimensin additionrecent trial results suggest cellcept may extend graft life patient survival none ofthe competitor products market demonstrated significant advantage cellcept sales ofzenapaxwhich used combination cellcept prevent theproduct received us regulatory acute transplant rejectiongrew approval october monotherapy december use combina valcytean oral antiviral medicine used tion copegusour proprietary prevent treat eye infections ribavirin productcentralised approval cytomegalovirus retinitisis steadily ofthe monotherapy combination replacing original formulation regimens granted european cymeveneas treatment ofchoice union summerpegasys valcyte first approved united swiftly launched germanythe states use hiv patients united kingdom eu markets european approval indica within months already cap tion followed expect val tured substantial market shareour cyte receive additional approval japanese filing monotherapy regions year use organ indication given fast track transplant patientscombined sales review statuspegasys valcyte cymevene rose mil approved countries world lion swiss francs widethe dispute icn pharma ceuticals ribapharm ribavirin april strengthened transplan patents settled january tation portfolio signing agree ment isotechnika codevelop protease inhibitorsviracept novel immunosuppressant isa invirase fortovaseposted com early trials suggest drug may bined sales million swiss francs effective less toxic although class ofmed immunosuppressants class icines still mainstay ofmany hiv regimenssales declined virology moving towards leader anintensely competitive protease ship pegasysa new generation inter inhibitor market discounts offered feron chronic hepatitis cmet developing countries mainly filing approval targets responsible decreasepositive pharmaceuticals major product approvals launches product generic name indication country copegus interferon alfa ribavirin hepatitis c eu usa switzer interferon alfa land australia dilatrend carvedilol severe chronic heart failure eu chronic heart failure japan kytril granisetron prevention treatment postoperative nausea vomiting usa mabtherarituxan rituximab combination chop chemotherapy eu switzerland aggressive nonhodgkins lymphoma australia neorecormon epoetin beta anemia patients solid tumours switzerland weekly dosing schedule patients hematological cancers eu pegasys peginterferon alfaa monotherapy hepatitis c eu usa pegasys copegus peginterferon alfaa ribavirin hepatitis c eu usa tamiflu oseltamivir treatment influenza b children adults eu japan prevention influenza b adolescents adults eu japan valcyte valganciclovir prevention cytomegalovirus infection aids patients eu usa xeloda capecitabine monotherapy metastatic breast cancer eu xeloda taxotere capecitabine docetaxel metastatic breast cancer eu switzerland xenical orlistat label change incorporating new data overweight obese patients type diabetes eu zenapax daclizumab pediatric renal transplantation eu includes supplemental indications cyclophosphamide doxorubicin vincristine prednisone launched japan japanese approval obtained new clinical data led fourth medicinefuzeon tto even quarter increase combined sales effective anticipated invirase fortovaseparticularly patients infected resistant strains important us marketwe ofhivmarketing applications developing new dosage strengths drugwhich worlds first fusion viracept invirase facilitate inhibitorwere filed september patient compliance enhance united states europeroche competitiveness ofthese products developing fuzeon partnership trimeristhe us european summer findings phase authorities granted fuzeon iii trial showed new hiv fast track review statuswe expect pharmaceuticalsing positive decisions filings product condition early production offuzeon strict prescribing rules would extremely complexand manufac apply manufacturers would turing facilities working around required institute patient safety clock ensure supplies programmes similar roches available greatest possible number ofpatients product sales ofxenicalthe worlds leading isapproved medicine weight loss weight controlwere line influenza medicinetamifluis overall decline market seg available worldwidefollowing mentdata submitted regulators approval last summer european first halfof role union treatment preven xenical treating overweight patients tion ofinfluenza bwhile sales nearly doubledthey still amounted relatively modest million swiss francsowing last years mild flu season northern southern hemisphere key products sales rocephin slightly previous yeardeclining result ofgeneric erosion europe last years relatively low influenza activity even years market rocephin remains injectable antibiotic ofchoicethanks high undiminished efficacythis prod uct posted sales ofover bil lion swiss francs sales ofroaccutaneaccutaneour type diabetes led label medicine severe acnedecreased changes european union million swiss francsthe approval ofthe medicine type decline due primarily tighter diabetes canada australia prescribing restrictions united recentlydata landmark trial statesoverallhoweversales xendosdemonstrated weight loss better expectedalthough roac regimen combining xenical cutaneaccutane went offpatent andlifestyle changes significantly united statesits biggest marketin better lifestyle changes alone februaryit face competi inpreventing type diabetes tion generics late second halfofthe yearin novem dilatrend posted sales million ber december fda granted swiss francsa doubledigit increase licences two generic versions ofthe previous yearapproval pharmaceuticals market product chronic heart nership glaxosmithklineroche failure japan severe chronic planning market novel oral heart failure europe strength intravenous formulations ened dilatrends position seg offer benefits patients mentfindings major study physiciansapplications filed shown starting patients early european us approval treatment dilatrend tomarket ibandronate postmeno ace inhibitor significantly pausal osteoporosis improve clinical outcomes mild tomoderate heart failure roche consumer health sales ofnonprescription medicines clinical development ofibandronate otc businessroche consumer ahighly effective bisphosphonate health rchdeclined local treatment prevention ofosteo currencies swiss francs porosisis moving ahead wellin part million swiss francs weak us sales ofaleve latin americas currency problemsparticu larly devaluation ofthe argen tinian pesowere two factors hamper ing growth last yearsales ofaleve united stateswhere brand marketed joint venture bayerwere latin america unable offset effects offalling currencies despite price adjustments made marketssales markets account ofour busi nessgrew rate factorscoupled building strong competitive strong swiss franchad negative impact operating profitwhich brands creating lasting value declined million swiss moreover ability develop francsebitda decreased million swiss francs brands equips us respond roche consumer healths key difficult challenges facing us brandsposted good growththe many markets exception redoxonwhich gener ates halfofits sales latin richard laube head roche consumer health america pharmaceuticalsresearch development consumer selfmedication substantial number new products expected medium term roche research based distinctive inno vation model see clear speciality skin care strategy partnerships play analgesics gastrointestinal products key roleapart roches cold remedies powerful inhouse research organisa sales therapeutic area others tionthe pharmaceuticals divisions rd network also includes genentech vitamins chugaiwhich function largely independent research satellitesin additionroche optin rights programmes ofexternal devel opment organisations created bioxellset basilea pharmaceuticathis leading otc brands source ofpromising compounds change sales local pipeline product uses millions chf currencies aleve naproxen analgesic agreements concluded supradyn multivitamin companies last yearroche bepanthen skin care ranks among industry leaders rennie antacid terms oflicensing redoxon vitamin c roche currently january pursuing pharmaceutical research projects inhousein new molecular entities nmes entered phase entered phase opment increased significantly clinical testingthe pharmaceuticals past two yearsthe seam division currently nmes less rd process estab development pipelinethis includes lished recent years promotes better optin opportunities potential decisionmaking thus contributes new medicines genentech creating greater future value develop chugai projects roche hasthe right licensein ongoing initiatives concentrating anyprojects chugai seeks optimising productivity apartner outside japan south focus value gen korea erated project quan tityprogress achieved increased number ofpromising implementing number oftools nmes compared result compound selection profiling ofstructural adjustments phar early research stagethese maceutical rd organisationthe harmonised across research number ofprojects phase ii devel centres pharmaceuticals pharmaceutical rd network also includes numerous alliances col laborations major industry science institutions around globe one example partnership decode geneticswhich last years led identification ofthirteen genetic risk factors common diseasesincluding stroke rheumatoid arthritis schizophre niaas result ofthese discoveries roche pharmaceutical research already investigating various new drug targetssuch glucokinase activators innovative way manage treatment ofdiabetesin roche decode entered research activities roche new threeyear alliance group allows us exploit synergies outlook roche expects pharma generate competitive knowledge ceuticals divisions organic growth ultimately create medicines enhanced launches ofpegasys fuzeonour oncology diagnostic products provide greater business continue strong growth trend thanks key prod benefits patients ucts mabtherarituxanxeloda herceptinneorecormon cell jonathan kc knowles head research cept also remain growth drivers anticipate established products rocephin roaccutane research projects accutane remain important major therapeutic areas january revenue earners lose current prominence generic erosion metabolic disorders virology next five years roche plans oncology vascular diseases file new drug applications urogenital diseases key therapeutic areas oncology inflammatory diseases hivaids anxietydepression central nervous system weintend additionally strengthen portfolio continuing inten sive inlicensing activities pharmaceuticals division looking outperform global marketwith divisions strong pharmaceuticalsdelif enilepip dednapxe yllaitnatsbus noitacidni iii esahp ii esahp esahp esahp noisnetxe enil rojam eman cireneg epyt tcudorptcejorp aera cituepareht aimena detalerrecnac ro aimena laner tnemtaert aimena noitareneg txen r aimena aimena tnemtaert aimena r yparehtoidar ni ateb niteope nietorpocylg nomroceroen sisoropoetso fo noitneverp dna tnemtaert etanordnabi etanohpsohpsib etanordnabir enobnoitammalfni sitirhtra diotamuehr ni rotibihni esanik r sitirhtra diotamuehr ni rotibihni esanik r sitirhtra diotamuehr ni bamixutir ydobitna lanolconom arehtbam setebaid epyt rotibihni emyzne r msilobatem setebaid epyt rotaludom rotpecer raelcun r setebaid epyt rotaludom emyzne r setebaid epyt rezitisnes nilusni r anapaj ni tnempoleved tatsilro rotibihni esapil lacinex noitacidni tnecseloda setebaid fo noitneverp yteixna dna noisserped rotaludom rcpg r metsys suovren noisserped rotaludom rcpg r yteixna dna noisserped rotaludom rcpg r esaesid sremiehzla rotibihni emyzne r sruomut dilos enolihtope rotibihni emyzne r ygolocno siseme rotaludom rcpg r siseme rotaludom rcpg r sruomut dilos bamuzutrep ydobitna lanolconom r sruomut dilos rotibihni emyzne r sruomut dilos rotibihni emyzne r recnac nairavo bamomutmep ydobitna lanolconom r recnac tsaerb ydobitna lanolconom r sruomut dilos nacetomolfid rotibihni emyzne r sruomut dilos rotibihni emyzne nb r sruomut dilos binitolre rotibihni esanik avecratr recnac tsaerb ni esaesid enob citatsatem etanordnabi etanohpsohpsib tanordnob recnac tsaerb fo tnemtaert tnavujda bamuzutsart ydobitna lanolconom nitpecreh aimekuel citycohpmyl cinorhc bamixutir ydobitna lanolconom arehtbam noitanibmoc citatsatem dna tnavujda enibaticepac adolex recnac noloc fo tnemtaert recnac tsaerb tnavujda amhtsa tsinogatna nirgetni r yrotaripser amesyhpme tsinoga rotpecer raelcun r amhtsa tsinogatna nirgetni r noitcejer tnalpsnart laner etuca rotibihni nirueniclac r tnalpsnart noitcefni surivolagemotyc fo noitneverp rivolcicnaglav eugolana edisoelcun etyclav noitatnalpsnart nagro dilos ni ytivitisnesrepyh civlep reddalb evitcarevo tsinogatna rcpg r ygoloru ecnenitnocni yraniru dexim dna sserts rotaludom rcpg r ecnenitnocni yraniru sserts rotaludom rcpg r ytivitisnesrepyh civlep reddalb evitcarevo tsinogatnarcpg r noitcefni vih rotibihni esaetorp r ygoloriv noitcefni vih rotibihni esatpircsnart esrever edisoelcunnon r c sititapeh rotibihni esaremylop r eugolana edisoelcun noitareneg wen r c sititapeh gurdorp nirivovel strawlatineg nietorpnoisuf rg p noitcefni vih editrivufne rotibihni noisuf noezuft r noitcefni vih rotibihni noisuf r c sititapeh nirivovel eugolana edisoelcun noitareneg wen nirivovelr noitalumrof cirtaidep rivaniuqas rotibihni esaetorp esavotrof b sititapeh cinorhc aafla norefretnigep norefretni detalygep sysagep noitalumrof wen noitcefni vih etalysem rivaniflen rotibihni esaetorp tpecariv bhcetneneg hguorht noitapicitrap ydobitna nlm esaesid lewob yrotammalfni ydobitna lanolconom ydobitna pdl remrof emordnys yranoroc etuca tnemgarf ydobitna lanolconom baf ft yparehtomehc htiw sruomut dilos nitsava ydobitna fgevitna nitsava noitareneged ralucam detalerega tnemgarf ydobitna lanolconom baf dma sisairosp bamuzilafe ydobitna adcitna milenax yllamrof avitpar sitirhtra diotamuehr amhtsa bamuzilamo ydobitna egiitna rialox biaguhc hguorht noitapicitrap amoleym elpitlum ydobitna lanolconom mha sisoropoetso enomroh dioryhtarap tnanibmocer shc recnac tsaerb lxt etamatulgylop chc sesatsatem enob ydobitna lanolconom lac sisoropoetso evitavired nimativ de esaesid traeh yranoroc tnadixoitna ob siseraportsag tsinoga nilitom mg ymotcetapeh tsop rotareneger revil lav egahrromeh dionhcarabus savetna sitirhtra diotamuehr ydobitna lanolconom arm nemow lasuaponemtsop ni sisoropoetso lch enefixolar atsive aimetahpsohprepyh lch remaleves leganer nemow lasuaponemtsop ni recnac tsaerb elozortel aramef cseitinutroppo nitpo sruomut dilos tnega gnitegrat ralucsav aaxmd amositna recnac gnul llec llamsnon tnemgarf ydobitna lanolconom bafareht egahrromeh dionhcarabus tsinogatna rotpecer nilehtodne vxa navoxa sisairosp rotaludom rotpecer raelcun lab acituecamrahp aelisab amezce dnah cinorhc dica cionitersic lab noitcefni lairetcab citoibitna lab noitcefni lagnuf lagnufitna lab noitcefni lagnuf lagnufitna lab esaesid ralucsavoidrac tsinogatna rotpecer nilehtodne pps r ledeeps ni era eseht fo enilepip tnempoleved snoisivid slacituecamrahp eht ni semn yltnerruc era ereht ton yam stcejorp emos snosaer evititepmoc rof srentrap lanretxe ni dna ii esahp ni era gnitset lacinilc esahp deretne evah esahp tnempoleved egatsylrae deifitnedi neeb evah akinhcetosi secneics nohpyrg delifiii esahp noitadilosnoc lluf b rividem etutitsni sciteneg tcudorp eht esnecil ot thgir eht sniater ehcor c nci enilkhtimsoxalg tnempoleved lacinilc ot lacinilcerp morf noitisnart esahp negsserts cedihcetneneg sreetnulov yhtlaeh ni seiduts laitini esahp siremirt slacituecamrahp yromem stneitap ni seiduts gnidnifesod dna ytilibarelot ycaciffe elacsllams ii esahp noruoga secneicsoib nasok ycaciffe dna ytefas fo noitamrifnoc lacitsitats rof stneitap ni seiduts elacsegral iii esahp semn seititne ralucelom wen stneserper epyteulb yllil ile hcetneneg yraunaj fo sa tnerruc yrewerb nirikemyzneg amositna sitravon nespi ruofuaeb isohcetneneg oncology portfoliothe rollout pegasys fuzeon integra tion ofchugai expected fuel solid doubledigit growthwe anticipate synergies resulting integration ofchugai take full effect division remains committed raising operating profit margin towards next two years pharmaceuticals christian artificial heart valve taking anticoagulant whose effects monitored reg ularly blood tests roches coaguchek device enables patients monitor coagulation status suits christians active lifestyle perfectly small enough christian take everywhere provides reliable information vital health tools networking organising analysing data increasingly demand kinds healthcare settings laboratories hospitals patient selftesting challenge translating raw data actionable healthcare information one major tasks addressed diagnostics divisiondiagnostics division brief change change local millions chf chf currencies sales diabetes care near patient testing centralized diagnostics molecular diagnostics applied science ebitda operating profit rd expenditures employees diagnostics diagnostics division extended global market leadership sales business areas grew ahead market divisions five geographic regionsas well gaining market share also increased prof itability addition systematic customer focus market development number strategic initiatives reshape expand division making supplier diagnostic tests systems also provider actionable health information helped us deliver strong performance research devel opment alliances licensing internal venture projects key components helping drive process forward diagnostics market ofthe divisions busi ness areascontinued aboveaverage gains diabetes care molecular diagnostics reflect innovative strength focused market develop ment activities ofthese two business areasin roche diagnostics fur ther strengthened position worlds leading invitro diagnostics companyexpanding global market share compared divisional profitability also increased operating profit million swiss francs ebitda advancing million swiss francsthe divisions operating profit ebitda margins respectivelyan increase percentage pointsincreased expenditureparticularly research industry leader continue development licensing activi play responsible active role tieswas offset strong sales growth helping shape market goal give doctors patients healthcare sales outpace market growth regions sales grew ahead payers optimal access reliable informa market ofthe five regions served divisioncontinued tion thus support enable timely growth north america driven effective decisionmakingat mainly diabetes monitoring businessmolecular diagnostics prod time critical us grow faster ucts elecsys immunochemistry market product linein europe dynamic growth seen continuedwith heino von prondzynski head diagnostics division important contributions resulting increased harmonisation ofana lytical platforms reagents clinical laboratoriesthe doubledigit market leadership extended sales gains recorded two biggest diagnostics division regions surpassedonce totalled million swiss francsa injapan asiapacificsales yearonyear increase local iberialatin america suffered currencies swiss francs result ofthe continuing economic againsales grew faster crisis latin america diagnosticshelping shape future roche isplaying active role shaping tomorrows invitro diagnostics mar ketto meet need actionable health informationroche develop ing solutions combine cutting edge diagnostics information management connectivitythe aim linkorganise translate diagnostic data information supports enhances clinical deci sionmakingthe division already begun creating infrastructure needed serve young fast growing market secured access necessary technologies mellibasean online service package diagnostics sales millions chf launched first mar ketsis one example ofactionable health information rocheusing mellibasedoctors health insurers provide diabetes patients individualisedevidencebased infor mation potential medical complications economic conse quences oftheir conditionexplain treatment options motivate patients adhere optimised treatment routine divisions active licensing policy creativityskill entrepreneurial continues play strategic roleby initiative throughout inter granting licences intellectual prop national organisationdesigned erty underpins existing busi identify mobilise untapped talent nessroche promoting wide use ideasthe initiative far led associated technology systems evaluation ofseveral thousand applies particularly pcrin business proposalsfocusing pro additionby acquiring licences jects likely result new health information areas products open new market division moving secure opportunitiesfour ofthese compa innovative strength future nies within companyare already generating revenue one year thanks internal venture process established initiated roche diagnostics also succeeded bringing together diagnostics strong growth business areas ficial pancreas use diabetes diabetes care thanks contin patientsone ofroches longterm ued success ofthe accuchek product goalsthe system longest linediabetes care extended monitoring capability market lead blood glucose monitor accuchek monitor scheduled ing segmentposting local currency initial launch germany growth ofonce againthe accu marketed medical chek advantage glucose meter professionals use mainly clinical one ofthe main growth driverssuc trials asiapacific japan others near patient testing applied science europe molecular diagnostics sales region sales business area north america diabetes care centralized diagnostics iberialatin america cessful launches europe japan introduction ofa new test strip continued global rollout ofaccu accuchek compact glucose chek compactthe first glucose meter meter scheduled giving featuring integrated test strips faster results less bloodit automatic checks ofstrip integrity make selfmonitoring ofblood glucose even easiera secondgeneration ver global rollout ofaccuchek active sion ofthe accuchek compact extremely lightweightuserfriendly include integrated lanc glucose meter provides test results ing systemis currently develop secondswas successfully completed mentthis innovation help us take leading position fast second quarter saw fda growing integrated spot monitoring approval ofaccuchek pocket com segment glucose meters combine passa software designed personal test stripsautomatic checks ofstrip digital assistants enables data integrity lancing system downloaded directly blood glucose meter february roche announced itsintention acquire medical accuchek monitora continuous device supplier disetronicthe worlds blood glucose monitoring system secondbiggest maker ofinsulin takes readings every five minutes pumpsthis move enable roche four daysmarks major milestone offer comprehensive solutions towards development ofan arti diabetes management cover every diagnosticsthing glucose selfmonitoring individualised insulin delivery using latest insulin pump technology proposed acquisition subject approval disetronics shareholders vote roches offer special general meetingand trans action also cleared antitrust authorities near patient testing sales roche near patient testingwhich supplies products services doctors officesambulances intensive care unitswere local currencies confirming business areas market leadership omni c become one ofthe main eight yearscontinuous market devel revenue earners segmentroche opment made near patient test diagnostics hopes duplicate ing leading supplier coagula success launch tion monitoring segmentthe trend omni sa new multiple parameter towards selfmonitoring ofcoagula blood gas analyser tion status patients continued resulting substantial sales mar increasing demand infor ket share growth coaguchek mation extensively networked product line growing accept rapidly available wherever ance ofcoagulation selfmonitoring neededaccordinglyroche diagnos tests health insurers increased ticsstrategy ofpackaging systems prescribing oforal anticoagulants global solutions combination reasons development products datacare roches technological leadership also positive impact area underscored sales launch ofa newimproved teststripscheduled primary care segment compact systems doctorsoffices roche sales hospital point ofcare confirmed leadership mar unitwhich supplies rapid diagnostic kets pointofcare urinalysis products emergency rooms multiparameter systems intensive care unitsgrew almost twice reflotron product lineroche diag fast marketthis good per nostics planning special web portal formance driven primarily sales direct communication cus ofcardiac assays ofomni ca tomersthis give physicians new analyser measures ten ofthe pathologists access information important critical care param andservices related divisions etersin first year market primarycare products diagnostics researchers patients broadest range diagnostics products market research market healthcare providers consumers applied science reagents innovative systems research labs service labs patients technologies medical biotech university hospitals hospitals consumers research food safety testing doctors offices biochemical reagents industry gps molecular diagnostics applied science pcrbased tests analysers lightcycler magna pure lc diagnosisidentifying disease predis rapid translation system position monitoring disease rts proteoexpert reagents progression response therapy research industry molecular diagnostics centralized diagnostics cobas amplicor cobas ampliprep integrated solutions vitro diag cobas taqman cobas ampliscreen nostic laboratoriesincluding every thing analysers test reagents intelligent workflow optimisation centralized diagnostics service offeringsinnovative diag modular analytics swa rochehitachi nostic parameters systems use cobas integra elecsys cobas core stago sysmex elecsys probnp laboratory diagnostics near patient testing near patient testing coaguchek cardiac reader products services pointof troponin omni reflotron care testingincluding coagulation combur test chemstrip monitoringelectrolyte blood gas accutrend gct datacare analysisrapid urinalysisclinical diabetes care chemistry analyserssystems rapid accuchek product line accu tests cardiac markersinformation chek compact accuchek management connectivity soft sensoradvantage accuchek ware active softclix diabetes care divisions centralized diagnostics molecu innovative blood glucose monitoring lar diagnostics near patient testing businesses serve needs health systemsservices information professionals linked together forpatients diabetes health labnetwork organisation professionals involved diabetes management diagnosticscentralized diagnostics sales test detects disease centralized diagnostics unitthe lead also helps doctors determine ing supplier ofintegrated analytical severity likely prognosis systems hospitals highvolume thanks probnpheart failure laboratoriesadvanced local detected early stage currenciesoutpacing market treatment significantly improved asubstantial marginthe increase nearly million symp wasdriven primarily elecsys tomatic heart failure patients immunochemistry integra united states aloneand roughly clinical chemistry product lines halfamillion new cases diagnosed hematology products market every year north america number european asian countries japanese partner sysmex roches presence segment hasbeen strengthened global rollout ofmodular analytics swathe first commercially available serum work area combine high throughput clinical chemistry immunoassay testing single plat formthe platform configured individual laboratoriesneeds iscapable ofprocessing roughly patient samples single passthus setting new standards ofefficiency productivity wide range ofhighquality tests roche lodged appeal available modular analytics swa judgement issued igen lawsuit isanother reason system april lower court hasreceived positive market united statesat time responsein menu discussions igen aim expanded include tests hor ofestablishing successful basis monescardiac markers markers future cooperation benefit ofbone metabolismthis brings parties number ofclinical parameters determined using molecular diagnostics roche elecsys analysers molecular diagnosticsthe market leader fieldposted sales year also saw successful launch increase local currenciesa growth ofelecsys probnpthe first commer rate well ahead cialfullyautomated test diagnos market averagethe business areas ing heart failure monitoring ampliscreen tests screening patientsresponse treatmentthe donated blood blood products diagnostics tests hepatitis b c donor blood japanthe nether sexually transmitted diseases delivered lands united kingdom especially robust growth broad portfolio ofhuman papillo gains business area reflect mavirus hpv patents acquired strong demand products based institut pasteur given us solid onthe highly sensitive polymerase basis developing marketing chain reaction pcr techniqueusing products early detection pcr technologyit possible copy hpv infectionhpv leading specific segments ofgenetic material cause ofcervical cancera disease millions oftimes overincluding even early diagnosis treatment tiniest fragments ofbacterial critical positive prognosis viral dnapcrbased tests thus afford late plan market means ofdiagnosing number hpv test expect supplant conditions rapidly reliably conventional pap smear testing mid term agreements like one signed unparalleled product pipeline institut pasteur another estab lishing strategic alliance qiagen develop commercialise inte grated nucleic acid diagnostics system diabetes care carefully targeted reinforcing near patient testing applied science leadership molecular diagnos business areas expected contribute tics major innovations next five years molecular diagnostics centralized diagnostics january roche diagnostics affymetrix signed agreement grants roche nonexclusive rights affymetrixs array instrument following successful launches technologies yearsone number ofmarketsa new version ofthe benefits ofhaving access highly sensitive amplicor hiv genechip technology test cleared united states enable us develop specific diagnos inmid use monitoring tic laboratory tests wide range patientsresponses aids therapy ofdiseaseswe confident synergies affymetrixs december fda also genechip platform roches pcr granted regulatory clearance technology establish new standards cobas ampliscreen systemfurther genetic testingmaking possible strengthening position tailor therapies individual patients blood screening sectorfda approval profilesand enhance ofroches pcrbased hepatitis c roche diagnosticsattractiveness hiv tests designed use apartner companies working system followed later month development ofmarkers guide roche tests already used screen individualised therapies diagnosticsthe global rollout ofcobas taqman fully automated pcr analyser isprogressing scheduleits big brothercobas taqmanwas success fully launched united states january together cobas ampliprep sample preparation sys temthese analysers represent another milestone ongoing efforts develop market new medical applications pcr blood screeninghpv tests women tests sepsis blood poisoning expected stimulate additional growth business areaas new pcrbased products use foodborne pathogens salmonella genomics listeria ofgenetically modified food constituents applied science roche applied sciencewhich makes reagents also new range ofresearch tests hightech systems scientific codeveloped innogenetics industrial researchrecorded sales detection ofdangerous bacteriaan growth local currencies important step road com maintained position last years prehensive portfolio ofdirect assays particularly challenging biotech busi microbial pathogens blood ness environmentthis strong per formance driven sales ofthe rapid translation system rts magna pure lc lightcycler pcr worlds first commercial system workflow system used primarily cellfree protein expressionroche fur genetics research genebased diag ther extended rts product range nosticslightcycler instrument launch ofthe rts amplifies genetic material proteomastera highly versatile system dna analysismagna pure lc wide range ofapplications module automates pcr sample proteomics preparation entry field ofscien applied science tific services roche applied science successful efforts expand isseeking develop completely new new marketsone example market segmentproteoexpert collaboration begun autumn aninternetbased information service idexx laboratories usa veteri designed help scientists working nary diagnosticsanother exten rts achieve fastermore sion ofour range ofproducts food efficient protein synthesisit testingnew lightcyclerbased tests developed cooperation biomax enable rapidprecise detection ofthe informatics ofgermany diagnostics launches ofadditional products connectivity order strengthen services expected market lead remain industry strengthen applied sciences market trendsetterroche diagnostics ide positionthese include system ally positioned continue active producing customised biochips use role shaping invitro diagnostics researchan expanded version ofthe market ofthe future lightcyclerthe new indycycler pcr instrumentand new service result ofan internal venture project offers synthesis ofspecial proteins industrial clients outlookthe divisions excellent per formance confirma tion pursuing correct strategy realignment initiated two years agofor expect thatdivisional sales continue advance well ahead ofthe market weremain confident ofachieving operating profit margin ofslightly better expect see dynamic sales growthparticularly europethe united statesasiapacific japan medium term intend strengthen market leadership launches ofinnovative new products continue pursue three pronged success strategy driven strong commitment rd invest absolute terms competitorsour internal venture process provides source ofnew business modelsproducts ser vicesand network ofalliances leading technology companies also continue systematically evolve division provider actionable health information targeted strategic initiativesin par ticularwe focus improvements innovations areas hos pital information management diagnosticsvitamins fine chemicals division brief change change local millions chf chf currencies sales vitamins carotenoids fine chemicals ebitda operating profit rd expenditures employees charges vitamin case impairment divisions net assets vitamins fine chemicals february roche announced intention divest vitamins fine chemicals division order concentrate fully core pharmaceuticals diagnostics businesses six months later group disclosed plans sell division dsm netherlands contract finalised february actual closing date depend soon authorities approve sale although economic conditions remained difficult vitamins fine chemicals division held market share posted substantial volume gains vitamins fine chemicals currencies increased second half ofoperating profit charges vitamin case impairment ofthe divisions net assets declined million swiss francs ebitda million swiss francsthe divisions operating ebitda margins thus respectivelyamong factors contributing weaker performance unfavourable exchange rate ofthe us dollar relative swiss francrestructuring onetime costs lower prices products volume ofproducts sold division rose substantial especially strong gains recorded new productsgrowth ani mal nutrition segment led divisions hyd feed supplement aggressively continued enzyme products robust volume strategy developing commer gains also posted food seg ment naturalsource vitamin e cialising new better products polyunsaturated fatty acids new carotenoids lycopenelutein deliver differentiated benefits zeaxanthinin fiercely competitive customersthis put us stronger cosmetics segment division scored major sales successes stable position extend global market vitamin c formulation stayc lead parasol slxa newgeneration uvb sunscreen launched last year markus altwegg head vitamins fine chemicals division vitamins ae cthe bcom plex vitamins products still global market leader steps experiencing significant pricing pres volume growth vitamins suresthe division took steps offset fine chemicals division recorded sales impact ofprice erosion imple ofalmost billion swiss francs menting additional programmes compared previous restructure manufacturing opera yearthis equivalent increase tions marketing infrastructure local currencies decline inswiss francsalthough last north america division con years anticipated market upturn tinued gain market sharedespite yet occursales growth local downward pressure pricesthe vitamins fine chemicalsdivision outperformed expectations fermentation process fully way sale dsmafter swiftly completing regionrecording yearonyear process living upto preparationsannounced last spring volume gains increased sales divisions high expectationsfollowing divest vitamins fine local currenciesin europe nega startup difficultiesthe newbiotin chemicals divisionroche decided tive trend noted early year plant grenzach able meet august sell division reversedby contrastthe situation increased demands vitamin netherlandsbased dsm groupas latin american markets remained midyearprices adversely core business ofdsm chemicals critical ofthe regions cur affected second halfof company strong life sciences rency problemsthe divisions overall howeveras supply exceeded demand focus division even share ofthe astaxanthin market neverthelessbiotin sales signifi solidly positioned extend market remained stabledespite downturn cantly better production technology leadership demand chiles salmonfarming ofvitamin c year benefit new opportunities sector sales growth especially asa result ofdelays construction growththe division remains firmly positive highpotential chinese work vitamin c plant dalry committed pursuing plans marketthe division posted substan scotland objectivesall ongoing capital expendi tial growth local currency terms ture restructuring projects asiapacific region forexamplewill implemented asiapacific food cosmetics pharmaceuticals sales region sales customer segment europe africa animal feeds north latin america strategic investments production division continued focus plannedany residual liabilities relat research vitamins fine research efforts developing innova ing vitamin case remain chemicals division reinforced lead tive new products efficient roche groupnegotiations premix supplier opening new manufacturing processesin dsm finalise contract stateoftheart plants feed pre move designed support divi successfully concluded february mixes chilehungary vietnam sions initiativeaimed food premixes china reducing costs ten years south africa another anew biotech centre opened branded vitamin products successful year divisions pre grenzachprogress initiative supradynberocca redoxon mix business trackdivisional research units continue marketed roche developed number ofnew formula consumer healthour nonprescrip construction work worlds tionsincreasing level ofdiffer tion medicines businessand advanced vitamin e manufactur entiation existing product lines therefore part ofthis transaction ing facility proceeding sched steppedup efforts drive innovation ulein sisseln switzerlandat reflected number ofnew grenzach germany site production patent applications filedwhich dou ofvitamin b using industrial bled compared vitamins fine chemicals since roche supported phelophepa health train clinic rails brings affordable primary health services people living rural areas south africa roche provides operating funding roche health clinic whose staff also visit area schools train stop educate people health issues raise public aware ness specific problems every year people treated phelophepa health train besides providing general medical services dental eye care psychological counselling phelophepa project also aims help people help volunteers every commu nity visited train attend basic health education course act multipliers passing learned othersin communitiespeople environment human resources safety environmental protection social involvement three distinct areas common concern people last year introduced roche connect give everyone works roche chance share financially companys successand continued promote corporate culture rewards performance ongoing efforts enhance safety environmental protection resulted reductions energy consumption emissions harmful pollutants benefiting employees communities roche facilities located remained actively involved efforts overcome critical lack healthcare affects many people developing countries people environment human resources healthy growth leads rise headcount healthy sales growth posted divisions led toselective affiliate staffing increases year end roche group employed people around countriesthe diagnostics division recruited new employeespri marily europe north america pharmaceuticals division headcount mainly result new hires united stateslatin america eastern europethe con solidation ofchugai also contributed established culture rewards rise divisions headcount increasing number ofemployees performance promotes entrepreneurial injapan end thinking levels organisation total headcount increase figure roche connect employee equity plan resultthe cost ofwagessalaries opportunity employees share employee benefits rose million swiss francs directly roches success equity ownership programmes daniel villiger head corporate services promote employee identification roche new programme called roche connect launched aim ofgiving employees human resourcesworldwide opportunity pur headcount division year end chase roche nonvoting equity securi change change ties genussscheine discount pharmaceuticals thus participate groups success diagnostics end offebruary vitamins fine chemicals programme introduced others countriesaround ofthe employ roche group ees countries signed roche connect farthe pro headcount region year end gramme scheduled rollout europe countries switzerland north america also saw launch ofa new latin america nonvoting equity security option pro asia gramme highlevel employeesas japan group buys underlying securi africa australia oceania ties equity instruments total stock marketthere nodilution ofthe value ofroche securities adding value performance performancebased compensation ued activities enhance system introduced four years ago leadership competencies remain progressively extendedwith high priority division financial incentives managers made considerable progress towards linked closely contri developing compensation incen butions increasing companys tive programmes reward outstand valueone component value ing achievements oriented performance management system introduced key human resources focus bedeveloped diagnostics division last year formulation ofleadership principles pharmaceuticals division divisional managers based human resources activities roches corporate leadership philoso focused establishing sus phythese implemented tainable leadership performance part ofthe remuneration culturethis supported managers eligible variable compen anexpanded global human resources sation packages related even function within divisionfrom closely goal achievement talent identification leadership performance leadership development based global standards expanded among roches global human resources initiatives rollout ofour executive develop intensified talent development ment programme collaboration junior leadership process london business school contin launch ofan assessment develop human resources ment centre managers advanced stages oftheir careersthese com plemented global learning development programmes individ uals teams support successful implementation ofroches business strategy dsm acquire vitamins fine chemicals division february roche signed contract sell itsvitamins fine chemicals divi sion netherlandsbased dsm groupthe transaction still subject approval antitrust authorities expect close sale firsthalfofdsm agreed honour current terms condi tions ofemployment ofthe divisions employees provide postretire ment benefits health coverage atcurrent levels higherongoing restructuring programmes division completed planned human resourcessafety environmental protection sustainability safety environmen tal protection crucial issues rocheas continuous demonstra ble advances areas make genuine measurable contribution sustainable developmentroche firmly believes sustainable busi ness practices key success forwardlookinginnovative com pany several decades steadily reducing emissions theairwater soilin recent years regard efforts behalf achieved mainly improving existing manufacturing safety environmental protection processes replacing fundamentally new ones ecoefficiency sustainability theadditional advantage ofreducing merely obligation energy consumption waste volumes society part parcel corporate activities roche systematically implements corporate healthsafety hans knzi head corporate safety environmental protection environmental protection standards business charter sustainable development developed inter energy consumption associated national chamber ofcommerce co emissions implementing guidelines formulated chem process optimisations ical industry 's worldwide responsible care programmein particularwe contributions sustain subscribe precautionary princi able development gained us ple principle ofecoefficiency number ofhonoursincluding award san francisco bay area accordinglywe remain committed business environmental network increasing ecoefficiency ofour forroche palo alto california manufacturing operations reducing usa energy reduction safety environmental protection safety environmental protection expenditure millions chf environmental stewardship roche one ofthe swiss firms investment continuously participated interna operating costs tional programmes safe man total expenditure agement ofchemicals oecdicca ceficthe aim ofthese programmes evaluate environmental impact improve knowledge environmental programmesand yet environmental protection group substances used worldwide large another clean industry award wide energy conservation efforts con quantitiesroche also major con facility cuernavacamexicoin tinued successfully year tributor international chemical additionseveral roche facilities gained reviewsupported variety ofcam industrys long range research initia iso certification paignsenergy consumption tivewhich investigating impact reduced substantial oftrace amounts ofchemicals healthsafety environmental humansanimals environment protection expenditure came additiona special campaign supports national research pro million swiss francsor launched reduce co emissionsin jects similar objectives ofsalesthe increase due primarily accordance agreements reached new environmental protection environmental conferences rio concern rocheas equipment new production facili kyoto johannesburgroche member ofvarious national ties integrated se controls intends decrease emissions international bodieshas follow greenhouse gases thus ing eus deliberations strat accidents incidents make active contribution reduc egy future chemicals policyin previous yearsthere major ing climate changein cam february european commis incidents group facilities paign resulted decrease co sion published white paper contain number ofincidents emissions ing proposals new european legis declined yearearlier level lation chemicalsinitial drafts severity frequency group goal elimina legally binding regula accidents declined significantly tion ofhalogenated hydrocarbon com tions directives expected comparison positive pounds cooling systems fire spring proposed new regis results due toour uncompromising extinguishersby steadily replacing tration procedurebroad interpreta commitment training develop halogenated hydrocarbons tion ofthe precautionary principle ment ofse officers agents alternative technical solu additional bureaucratic hurdles employeesin training focused tionsroche working help protect would seriously jeopardise europes risk managementrisk analysis ozone layer reduce green attractiveness centre incident management aspects house effectin efforts led chemical pharmaceutical industry occupational medicine reduction total inventory ofhalogenated hydro total se audits con carbons roche facilities ducted countriesthe visits confirmed high safety emissions ofvolatile organic com health environmental protection pounds voc roche plants standards maintained group reduced overall facilities past ten yearsin voc emissions cut comparison safety environmental protectionsocial involvement many faces good corporate citizenship global company roche contributes daily improving quality oflife ofpeople around theworldwe directly involved community service projectsmake donations charitable causes work partnership wide range ofnonprofit organisationsat roche good corporate citizenship extends environmental protection promoting public health awareness education providing humani tarian aid innovation central roches look innovative ways pharmaceutical diagnostic improve healthcare delivery devel oping countriesbecause ofthe close research also breaking alignment diagnostics new ground resolve healthcare therapeutics businesseswe able contribute effective use challenges developing world ofthese countriesvery limited far seemed insur resources mountable train hope assures access basic medical carerelieving franz b humer chairman board directors ceo heavy burden ofdisease developing countries requires sweeping improve social involvement phelophepa health train facts figures one ofits leading sponsorsat cere health train began operating consisted three coaches mony may roche hon today boasts coaches weighs tonnes fully equipped provide oured awardpresented general medical services dental eye psychiatric care south african cabinet ministerfor phelophepa spends weeks year travelling country permanent staff itscontribution health train work students preparing careers variety medical healthrelated fields return days volunteer service students gain coach housing trains valuable practical experience people treated train health clinic officially renamed every year far health train brought basic medical services one roche health clinicin recognition million people remote parts south africa roches longstanding continuing trains annual stops around members local community supportroche assumed full finan come aboard fiveday course provides basic information subjects cial responsibility clinic first aid hygiene infectious diseases sound nutrition family health provides funding maintenance method helping people help brought significant salariesmedical equipmentconsum lasting improvement health people living regions visited train ables training materialssince phelophepa thus contributing sustainable development rural south africa roche also contribut ingto initial inservice training activities help clinics staffstay ments infrastructureor even creat abreast ofnew advances primary ing infrastructure none care provide best possible existsfor startthis means address services ing basic needs sound nutrition clean waterand also involves building united front hiv providing access good primary care partnerships international raising awareness ofhealth problems organisations unaids creating institutional national governmentsrelieforganisa resources needed provide spe tions industry critical role cialist treatmentnobody meet play combating hivaids challenges alonebut thethird worldas founder member broad coalition ofpartners works ofthe accelerating access initiative togethersignificant progress possi brought together five blesouth africas phelophepa project unagencies five researchbased impressive example ofjust pharmaceutical companiesroche much achieved supporting effort phelophepa whichtranslated liter important steps taken allymeans goodclean medical care recently ensure broader access name ofa mobile clinic rails treatments hivaidsgovern made possible alliance ofhealth ments become actively care transport companiesgovern involved fight aids ment agencies universitiesthe time recognising project delivers basic medical services obligations imposed international large numbers ofpeople remote trade patent lawspharmaceutical rural areas ofsouth africaroche companiesfor parthave made supporting train ofhopeas major concessions drug pricing local people call itsince roches position matter clear social involvementwe intend make profit aids drugs africamoreoverwe refrain submitting patent applications asserting existing patent rights antihiv products least developed countries countries subsaharan africa classified least developed developing countriesand particu larly subsaharan africawe supply major drugs invirase vira cept terms even favourable offered manufacturers genericsin case ofviraceptwe tific medical expertisethere able reduce prices even plans expand initiative future sharply thanks improve help ofdonor fundingcare ments manufacturing process also serving model important therapeutic agent organisationshiv projects africa additionroche diagnostics sup plying highly sensitive pcr tests diagnosing hiv monitoring antiretroviral therapy massively reduced prices important measures fight hivaids although low prices alone solve problem affordability one ofmany barriers healthcare developing nationsroche therefore also supports projects promote prevention andhelp improve infrastructure carea pilot project initiated early conjunction pharmaccess international facilitate access hiv treatment kenyaugandacte divoire senegalis success fully underwayinfrastructure dis tribution problems caused initial delay ofalmost one year getting project offthe groundroche funds pilot projectin addition sup porting medicinesdiagnostic kitseducation programmes scien social involvement finance year great change roche groupsignificant steps havebeen taken towards strategic objective creating unique healthcare company focused two hightech pillars pharmaceuticals diagnostics vitamins fine chemicals division longer considered core activity consequently divested dutch group dsmin october alliance chugai completedimproving roches presence worlds second largest pharmaceuticals market quantum leap underlying core businesses pharmaceuticals diagnostics continue achieve improved operating results strong cash generationthese positive developments overshadowed three factorsan impairment charge caused divestiture vitamins fine chemicals businesssignifi cant litigation expenses impact setting new basis manage ment equity portfoliofor many years active management roches liquid funds longterm investors perspective made major contri bution net incomesince downturn world equity markets roche incurred substantial unrealised losses onits financial assetsthese unrealised losses consistently reported roches balance sheet byproactively revising accounting policies line expected developments ifrsroche created renewed financial flexibilitythe related onetime impairment opens way manage liquid assets objective generating financial incomereducing debt investing strategic development two core businesses impact three factors results reported net loss billion swiss francsgoing forward roche solely focused two successful profitable cashgenerating core businesseswhich generated anet income billion swiss francs financefinancial review highlights millions chf figures reported figures reported financial statements adjusted basisa change change sales ebitdab operating profit net income adjusted figures used internal management roche group represent results thegroups underlying ongoing operations exclude special items include continuing businesses see pages full description reconciliation b ebitda earnings interest financial income tax depreciation amortisation including impairment corresponds operating profit depreciation amortisation including impairment core pharmaceuticals diagnostics businesses delivered good results shown adjusted results pharmaceuticals delivered particularly strong results oncology transplantation areas addition generic competition roaccutaneaccutane theunited states came later expected results also include three months worth results chugai diagnostics showed continued growth business areas especially diabetes care financial impacts repositioning roche group well certain litigation matters huge impact reported results litigation costs vitamin case genentech legal cases totalled billion swiss francs book value net assets vitamins fine chemicals division writtendown billion swiss francs based sales price agreed dsm although partly offset book gain billion swiss francs part disposal nippon roche single largest impact respect financial assets falls world markets last two years particularly last six months resulted net unrealised losses billion swiss francs groups equity portfolio con sistent ongoing restructuring groups financing treasury operations group decided proactively revise accounting policy line us healthcare peers expected developments ifrs give appropriate presentation financial statements following accounting policy revision major part previously unrealised losses deferred equity writtenoff resulted onetime expense billion swiss francs made positive sometimes painful progress towards repositioning roche groupwe exiting noncore activities fully focused successful pharmaceuticals diagnostics businesses roche finance providing solid platform value creation entrepreneurial development group erich hunziker chief financial officer financial review roche group repositioning millions chf chugai alliance chugai completed group well positioned move forward strategic objectives japan final purchase consideration acquisition accounting billion swiss francs although overall consolidated net cash outflow billion swiss francs cash contributions made chugai remain groups consolidated balance sheet annual ongoing effects acquisition accounting include million swiss francs amortisation million swiss francs depreciation acquisition accounting also resulted onetime net gain million swiss francs effectively selling nippon roche minority shareholders chugai fair value writeup million swiss francs inventories held chugai date acquisition writtenoff inventory turn months october resulting additional expenses million swiss francs million swiss francs first half pharmaceuticals division restructuring fundamental restructuring programme announced may largely com pleted additional costs million swiss francs future costs anticipated restructuring lead optimal cost structure focussed sales spend divestment vitamins fine chemicals business sale vitamins fine chemicals business completed subject regu latory approval expected close first half based signed agreement dsm impairment net assets division totalling million swiss francs hasbeen recorded reduced profitability business since initial announcement preliminary agreement dsm reductions market valuations businesses worldwide led agreed sales price vitamins fine chemicals business significantly lower previous book value reduction drives impairment charge part sale agreement liabilities respect vitamin case remain roche group additional expenses recorded million swiss francs represents resolution major litigation currently outstanding us customers estimate remaining likely litigation costs worldwide genentech legal cases following court judgement groups us subsidiary genentech recorded provision million swiss francs main litigation concerned relates alleged breach agreement genentech city hope medical center genentech appealing thejudgement however already announced groups halfyear results full provision recorded financial statements financial reviewtreasury financing group took steps restructure treasury financing operations thestrategic objective move high risk taking financial investments line groups healthcare peers time group evaluating options restruc ture debt financing aim reducing debt levels simplifying funding structure better aligning funding levels operating needs developments world markets reduced fair value groups equity portfolio resulted large unrealised losses deferred equity consistent strategic objec tives roche decided proactively revise accounting policy availableforsale financial assets future investments market value original cost sustained sixmonth period considered impaired loss automati cally recorded income statement rather deferred equity onetime impact revision accounting policy recognise unrealised losses billion swiss francs december impairment charge effect amounts reclassified fair value reserves equity retained earnings via income statement impact balance sheet value financial assets already recorded atmarket value since january impact net income chugai transaction net gain acquisition accounting inventory fair value adjustment writeoff pharmaceuticals division restructuring vitamins fine chemicals division discontinuing operation including tax impairment net assets vitamin case major legal cases impairment financial assets income taxes minority interests total impact financial review operating results millions chf sales doubledigit growth oncology transplantation diagnostics change change local chf currencies pharmaceuticals total prescription roche prescriptiona b genentech prescription japan prescriptionc otc diagnostics sales adjusted basis vitamins fine chemicals reclassificationa total sales pharmaceuticals division sales adjusted include reclassification sales vitamins fine chemicals division b excludes nippon roche classified part japan prescription segment c consists chugai october nippon roche january september strong performance oncology transplantation franchises prescription business afurther doubledigit growth diagnostics sales consolidation chugai october increased adjusted group sales local currencies million swiss francs chugai contributed slightly less percentage points groups growth percentage points growth pharmaceuticals total prescription business significant sales increase achieved spite adverse impacts generics roaccutaneaccutane particular second half sales pharmaceuticals accounted groups core businesses diagnostics geographically north america contributed europe japan rest world total group sales adjusted basis financial reviewoperating profit doubledigit increase margin improvement group pharmaceuticals diagnostics change change local chf currencies sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets operating income expense net operating profit adjusted basis adjustment items see pages total operating profit operating profit increased local currencies swiss francs almost billion swiss francs adjusted basis excludes vitamins fine chemicals business special items increase primarily driven sales growth improved cost structure result pharmaceuticals division restructuring gains approximately million swiss francs continuing product portfolio asset realignments pharmaceuticals diagnostics increased operating profit margin respectively group operating profit margin sales increase percentage points previous year gross profit increase swiss francs billion swiss francs gross profit margin improved percentage points reflects particularly strong growth highmargin pharmaceuticals diagnostics products effects continuing produc tivity improvements marketing distribution increase swiss francs billion swiss francs underproportional sales growth cost increases pegasys fuzeon product launches partially offset focused spend growth areas resulting restructuring marketing distribution percentage sales fell percentage points research development increase swiss francs billion swiss francs support strong research development pipelines core businesses intensified inlicensing arrangements research development costs percentage sales group level reached increase percentage point pharmaceuticals accounts groups research development expenses increased administration increase swiss francs billion swiss francs mainly due integration chugai corporate projects financial review amortisation intangible assets increase decrease swiss francs bil lion swiss francs local currencies amortisation charge increased mainly due acquisition chugai october fall swiss francs mainly driven foreign exchange movements significant part groups intangible assets denominated us dollars euros japanese yen roches amortisation charge currently almost sales continues significantly higher industry average following implementation ofrecent changes companies using united states generally accepted accounting principles usgaap longer required amortise goodwill instead must carry regular impairment review roche continuing amortise goodwill including held genentech required international financial reporting standards ifrs goodwill amortisation expense million swiss francs operating income expense net decrease swiss francs net expense million swiss francs million swiss francs reduction net expense mainly driven gains approximately million swiss francs continuing product portfolio asset realignments particular gain disposal neupogen million swiss francs second half divisional resultsin millions chf divisional ebitda operating sales operating profit third parties ebitda sales profit sales pharmaceuticals total prescription roche prescription genentech prescription japan prescription otc diagnostics group total adjusted basis adjustment items see pages group total pharmaceuticals total prescription roche prescription genentech prescription japan prescription otc diagnostics group total adjusted basis adjustment items see pages group total adjusted figures used internal management roche group represent results groups underlying ongoing operations exclude special items include continuing businesses seepages full description reconciliation financial reviewpharmaceuticals operating profit ebitda margins improved operating profit increased billion swiss francs representing sales ebitda totalled billion swiss francs ebitda margin increased strong result driven prescription business otc results weakened compared previous year total prescription sales increased local currencies primarily driven strong performance oncology franchise key products cellcept neorecormon partly offset impact generics roaccutaneaccutane consolidation chugai october contributed percentage points growth prescription business marketing distribution costs increased line sales increased costs launch new products pegasys fuzeon partially offset focused spend growth areas resulting pharmaceuticals division restructuring research devel opment pipeline complemented number inlicensing deals increased rd costs substantially due upfront milestone payments result also includes gain disposal neupogen million swiss francs due acquisition chugai order improve comparability japan prescription business reported separately consists nippon roche prescription business september chugai october consequently roche prescription business shown report excludes business japan years profitability roche prescription business improved operating profit margin genentech prescription business achieved another strong sales profit growth ebitda margin represents genentechs strong contribution groups operating cash generation operating profit genentech includes million swiss francs amortisation mainly arising acquisition genentech roche japan prescription business grew result acquisition chugai operating profit margin decreased due strength swiss franc relative japanese yen higher launch costsfor new products recurring acquisition accounting charges annualised basis acquisition accounting impacts amount approximately million swiss francs otc sales fell local currencies main factors weak sales aleve eco nomic difficulties latin america operating profit decreased million swiss francs primarily due decline sales startup costs new production facility absence second half gains product disposals part ongoing product portfolio streamlining intensified marketing efforts product rollouts second half operating profit margin compared diagnostics another strong result sales development significantly outperformed market overall growth rate local currencies sales growth high margin business areas molecular diagnostics diabetes care particularly strong operating profit increased million swiss francs ebitda million swiss francs profitability improved operating profit margin percentage points ebitda margin percentage points increased operating costs particular research develop ment licensing activities offset strong sales growth result consists costs corporate headquarters costs increased compared mainly due launch corporate initiatives financial review financial income expense net millions chf impairment financial assets impairment charge million swiss francs major impact groups results charge arises accumulated effects groups equity portfolio falls world markets last two years especially last six months groups revised accounting policy means significant falls would automatically recognised expenses accumulate deferrals equity underlying net financial income net financial income adjusted basis decreased million swiss francs excludes net financial expenses million swiss francs attributable vitamins fine chemicals business significant item gain million swiss francs disposal labcorp shares gains equity derivatives include million swiss francs respect locking part labcorp gains using derivatives excluding labcorp adjusted financial income net expense million swiss francs broadly expected net income equity investments excluding labcorp million swiss francs difficult market environment limited possibilities realise gains interest income million swiss francs decrease relative prior year caused falls interest rates interest expense fell million swiss francs fall interest rates less impact amortisation rates discount debt instruments fixed full breakdown net financial income given note financial statements income taxesin millions chf major events uneven tax impacts result tax expense million swiss francs pretax loss million swiss francs impacts shown table note significant impairment financial assets causes pretax lossof billion swiss francs little tax impact investments held lowtax jurisdictions adjusted basis effective tax rate increased mainly due operating income making increasingly higher proportion pretax income previously case also increasingly positive impact genentech chugai pretax profits results increasing tax rate consequently although adjusted pretax income lower tax expense higher associated companies minority interests millions chf reported results part costs genentech legal cases attributable minorities underlying expense minority interest continues increase overall contribution genentech net income increases comparative results income asso ciated companies consists mainly income labcorp period prior june time accounted associated company remaining associated companies notably basilea pharmaceutica currently generating net expense financial reviewnet income millions chf reported basis various major events result net loss million swiss francs adjusted basis net income lower million swiss francs increase operating profit offset lower financial income proportionately higher tax charge cash flows net liquidity millions chf cash flow statement cash generated business operations operating cash flows operating activities income taxes income taxes paid activities operating activities financing activities investing activities net effect currency translation cash increase decrease cash groups operations continued show strong growing operating cash generation billion swiss francs driven continued growth ebitda operating cash surplus largely absorbed payments totalling billion swiss francs respect major legal cases payments follows vitamin case eu fine million swiss francs vitamin case various settlement payments made direct indirect vitamins customers united states elsewhere million swiss francs igen litigation payment million swiss francs collateral deposit account pending resolution litigation operating cash flows increased due additional contribution million swiss francs paid one groups us pension plans increase taxes paid reflects settle ment increased tax expenses noted includes taxes paid labcorp gains significant financing cash flows payment dividend shareholders billion swiss francs repayment due date billion yen samurai bonds cash outflow billion swiss francs outflows also include billion swiss francs cash paid genentech repurchase shares third parties investing cash flows include impacts chugai antisoma alliances well bil lion swiss franc proceeds sale labcorp shares march july capital expenditure slightly increased major acquisitions divestments funds themajor cash outflows described taken groups marketable securities portfolio accounts remainder inflow year demerger vitamins fine chemicals division completed first half therefore divisions cash flows still included figures financial review net liquidity december december cash marketable securities financial longterm assets derivative financial instruments net equity instruments financial assets longterm debt shortterm debt total debt net liquidity net liquidity decreased billion swiss francs give million swiss francs significant outflows follows vitamin case payments billion swiss francs dividend payment billion swiss francs falls fair value marketable securities billion swiss francs large outflows partly offset cash generated operations ebitda totalled billion swiss francs three groups debt instruments lyons ii helveticus bullet bonds totalling billion swiss francs classified repayable within one year sale labcorp shares effect net liquidity simple terms transfer frommarketable securities cash similarly repayment samurai bonds effect areduction shortterm debt cash billion swiss francs certain major items foreseeable including proceeds demerger vitamins fine chemicals division settlement remaining vitamin case provisions proposed dividend payment repayment lyons ii helveticus bullet debt instru ments reduce cash affect net liquidity debt also reduced balance sheet millions chf change longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities total equity minority interests liabilities financial reviewforeign currency translation effects fall value us dollar relative swiss franc significant impact certain balance sheet headings particularly intangible assets longterm debt minority interests relatively high proportion us dollar denominated items effects movements euro japanese yen relative theswiss franc less significant impact chugai completion alliance chugai october significant impact balance sheet net acquired assets including fair value adjustments billion swiss francs billion swiss francs attributable minorities part disposal nippon roche increased minority interests million swiss francs provisions litigation vitamin case related payments totalled billion swiss francs reduces current liabilities partly offset billion swiss franc increase provision booked second half remaining provisions respect vitamin case classified shortterm igen litigation related payment million swiss francs collateral deposit account reduces current assets increases longterm assets provision genentech legal cases million swiss francs included noncurrent lia bilities longterm assets increased current assets decreased million swiss francs following reclassification certain genentechs investments longterm see note equity financing repayment samurai bonds reduced current liabilities billion swiss francs lyons ii helveticus bullet bonds book value bil lion swiss francs shown current liabilities payment dividend reduced equity billion swiss francs net loss period decreases equity sale labcorp shares means unrealised gain held within equity takenout equity recognised income statement impairment financial assets overall impact total equity effect transferred fair value reserves retained earnings via income statement groups obligation repurchase equity instruments connection sumo lyons v reclassified equity longterm debt discounted value billion swiss francs effects currency trans lation reduced net assets equity billion swiss francs movements property plant equipment intangible assets decreased billion swiss francs due million swiss franc impairment charge vitamins fine chemicals division due depreciation amortisation fall us dollar minor ity interests stable increase respect chugai largely offsets decreases result ing share repurchases genentech fall us dollar strong financial condition group remains solidly financed however recent events significant impact equity including minority interests representing total assets compared end spite total assets still financed longterm net liquidity reduced billion swiss francs financial review subsequent events february roche disetronic announced plans group would acquire infusion systems division disetronic disetronic world leader research development insulin pumps treatment diabetes proposed acquisition subject approval competition authorities disetronics shareholders total net cost acquisition expected approximately billion swiss francs foreign exchange rates exchange rates swiss franc december average december average december usd eur gbp jpy chfusd exchange rate j f j j n financial reviewthe adjusted basis concept adjusted basis managements view groups ongoing operations presented consistent comparable basis consolidated results roche group significantly influenced various special items also changes international financial reporting standards years improve thevisibility underlying business adjusted results also presented adjusted results used internal management business represent results thegroups underlying ongoing operations principles used compile adjusted results applied consistent basis major concepts follows adjusted results include gains losses continuing product portfolio asset realignments sales income newly acquired products impacts sales income patent expiry withdrawal disposal existing products impairments longterm assets part major restructuring costs normal ongoing restructuring gains losses sales marketable securities adjusted results exclude gains losses arising disposal fully consolidated subsidiaries associated companies discontinuing operations sale spinoff whole business onetime costs major restructuring fundamental reorganisations charges exceptional legal cases transition effects changes revisions accounting policies specific items excluded adjusted results adjusted results exclude gain part disposal nippon roche nonrecurring charges relating chugai transaction results vitamins fine chemicals division including impairment net assets additional charges relating vitamin case nonrecurring costs pharmaceuticals division restructuring additional charges respect major legal cases impairment financial assets adjusted results exclude results vitamins fine chemicals division including impairment net assets additional charges relating vitamin case nonrecurring costs pharmaceuticals division restructuring financial review income statement millions chf figures reported figures reported financial statements adjusted basis change change sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets chugai transaction pharmaceuticals division restructuring vitamins fine chemicals division impairment net assets vitamin case major legal cases operating income expense net operating profit financial income expense net impairment financial assets profit taxes income taxes profit taxes income applicable minority interests share result associated companies net income diluted earnings per share nonvoting equity security chf financial reviewreconciliation reported figures adjusted basisin millions chf reference numbers indicate corresponding notes consolidated financial statements sales operating year ended december third parties ebitda profit net income reported consolidated financial statements gains losses fully consolidated subsidiaries associated companies net gain part disposal nippon roche reduction total consideration paid chugai impact fair value adjustement chugai inventories discontinuing operations results vitamins fine chemicals division reclassification intercompany sales vitamins fine chemicals division sales third parties impairment net assets vitamins fine chemicals division additional charges respect vitamin case major restructuring nonrecurring costs pharmaceuticals division legal cases additional charges respect genentech legal cases transition effects changes revisions accounting policies impairment financial assets income taxes income applicable minority interests results adjusted basis sales operating year ended december third parties ebitda profit net income reported consolidated financial statements discontinuing operations results vitamins fine chemicals division reclassification intercompany sales vitamins fine chemicals division sales third parties additional charges respect vitamin case major restructuring nonrecurring costs pharmaceuticals division income taxes results adjusted basis financial review consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement millions chf year ended december sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets chugai transaction pharmaceuticals division restructuring vitamins fine chemicals division impairment net assets vitamin case major legal cases operating income expense net operating profit financial income expense net impairment financial assets profit taxes income taxes profit taxes income applicable minority interests share result associated companies net income basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security chf number shares per share information restated share split took place may seenote consolidated financial statementsconsolidated balance sheet millions chf december longterm assets property plant equipment intangible assets investments associated companies financial longterm assets deferred income tax assets longterm assets total longterm assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm equity instruments retained earnings fair value reserves total equity minority interests noncurrent liabilities longterm debt deferred income tax liabilities liabilities postemployment benefits provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total equity minority interests liabilities pm pro memoria nonvoting equity securities nominal value see note consolidated financial statements consolidated statement changes equity millions chf year ended december share capital balance january december nonvoting equity securities genussscheine balance january december pm pm equity instruments balance january movements year employee share option plan reclassification obligation repurchase equity instruments balance december retained earnings balance january net income dividends paid balance december fair value reserves balance january increase decrease fair value income expense recognised income statement deferred income taxes minority interests equity component new convertible debt currency translation gains losses balance december total equity december pm pro memoria nonvoting equity securities nominal value see note consolidated financial statementsconsolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital costs pharmaceuticals division restructuring paid costs vitamin case paid igen litigation payment collateral deposit account payments made defined benefit postemployment plans operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows financing activities proceeds issue longterm debt repayment longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid genentech stock repurchases financing cash flows total cash flows used financing activities cash provided operating financing activities cash flows investing activities purchase property plant equipment intangible assets disposal property plant equipment intangible assets acquisition subsidiaries associated companies products divestments subsidiaries associated companies products proceeds sale labcorp shares interest dividends received sales purchases marketable securities net investing cash flows total cash flows used investing activities net effect currency translation cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year consolidated financial statements notes consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards including standards interpretations issued international accounting standards board prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved forissue board directors february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement dateof financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change necessary comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd acompany registered switzerland subsidiaries hereafter group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enter prise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights companys share capital companies acquired year consolidated date operating control transferred group subsidiaries divested included date divestment companies acquired resold consolidated classified assets held sale carried fair value assets identified divestment following year reclassified assets held sale within current assets assets normally consist mainly inventories property plant equipment longterm assets investments associated companies accounted equity method com panies group exercises significant influence control isnormally evidenced group owns voting rights company interests joint ventures reported using linebyline proportionate consolidation method notes consolidated financial statementsforeign currency translation group companies use local currency measurement currency certain group companies use currencies namely us dollars swiss francs euros measurement currencies usefully represents results financial positions com panies given local economic conditions circumstances local transactions curren cies initially reported using exchange rate date transaction gains losses settlement transactions well gains losses monetary assets liabilities denominated currencies included income except deferred equity qualifying cash flow hedges upon consolidation assets liabilities group companies using measurement currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity divestment foreign entity identified cumulative currency translation differences relating foreign entity arerecognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied services rendered tocustomers deducting trade discounts volume rebates excluding sales value added taxes cash discounts recorded marketing distribution expenses revenues fromthe sale products recognised upon transfer customer significant risks rewards usually upon shipment royalty income recognised accrual basis accordance economic substance agreement revenues recorded earned theservices performed cost sales includes corresponding direct production costs related production overhead goods manufactured services rendered research development research costs charged income incurred exception buildings major items equipment capitalised depreciated development costs capitalised intangible assets probable future economic benefits flow thegroup intangible assets amortised straightline basis period expected benefit reviewed impairment balance sheet date develop ment costs charged income incurred since criteria recognition anasset met notes consolidated financial statements inlicensing milestone upfront receipts payments certain group companies notably genentech receive thirdparties upfront milestone similar nonrefundable payments relating sale licensing products technology revenue associated performance milestones recognised based achievement milestones defined respective agreements revenue nonrefundable upfront payments licence fees initially reported deferred income recognised income asearned period development collaboration manufacturing obligation payments made group companies third parties associated companies items charged income research development costs unless probable future economic benefits flow group normally evidenced regulatory approval case capitalised development costs amortised described practice means inlicensing milestone payments pharmaceutical products expensed incurred cases yet gained regulatory approval receipts payments consolidated subsidiaries genentech roche group subsidiaries eliminated consolidation employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned group operates number defined benefit defined contribution plans throughout world cost year defined benefit plans determined using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return planassets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested pension assets liabilities different defined benefit schemes offset unless group legally enforceable right use surplus one plan settle obligations plan pension assets recognised extent group able derive future economic benefits way refunds plan reductions future contributions groups contributions defined contribution plans charged income statement year relate taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based onincome property capital taxes included within operating expenses financial expenses according nature provision income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries made current inten tion remit earnings notes consolidated financial statementsdeferred income tax provided using liability method temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes leviedby taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows buildings land improvements years machinery equipment years office equipment years motor vehicles years investment grants similar assistance projects initially recorded deferred income inother noncurrent liabilities subsequently recognised income useful lives related assets repairs maintenance costs recognised expenses incurred borrowing costs capitalised assets acquired finance leases depreciated estimated useful lives payments made operating leases charged income straightline basis period lease intangible assets business combinations goodwill recorded intangible asset surplus cost acquisition fair value identifiable net assets acquired goodwill fair value adjustments treated assets liabilities acquired company recorded local currency company patents licences trademarks intangible assets initially recorded fair value assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost intangible assets amortised useful lives straightline basis estimated useful lives major classes intangible assets follows goodwill years patents licences trademarks lower legal duration intangible assets economic useful life maximum years notes consolidated financial statements impairment longterm assets recoverable amount asset higher net selling price value inuse less carrying amount carrying amount reduced recoverable value reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment arises useful life asset question reviewed ifnecessary future depreciationamortisation charge accelerated inventories inventories stated lower cost net realisable value cost determined first firstout method cash cash equivalents cash cash equivalents comprises cash hand time call current balances banks similar institutions readily convertible known amounts cash subject insignificant risk changes value definition also used cash flow statement equity instruments groups holdings equity instruments recorded deduction equity original cost acquisition consideration received subsequent resale equity instru ments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments december group revised accounting policy classification obliga tions repurchase equity instruments shown liability measured present value final obligation discounted using appropriate longterm pretax interest rate discount future amortised duration obligation recognised part interest expense income statement debt instruments debt instruments initially reported cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method extent debt instruments hedged qualifying fair value hedges hedged item recorded fair value discount net proceeds received principal value due redemption amortised duration debt instrument recognised part interest expense income statement issue convertible debt instruments cost liability portion initially calculated using market interest rate equivalent nonconvertible instrument remainder thenet proceeds allocated equity conversion option reported equity deferred income tax liabilities equity conversion option shares consolidated subsidiary portion net proceeds attributable option recorded within minority interest liability element subsequently reported amortised cost amortisation debt discount release deferred tax liabilities recognised income statement duration debt instrument value equity conversion option changed future periods limited conversion preferred stock substance financial liability rather equity instrument therefore classified longterm debt balance sheet related dividend payments treated interest expense notes consolidated financial statementsprovisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated provisions recorded estimated ultimate liability expected arise taking account foreign currency effects time value money contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices adjusted estimated transaction costs would incurred actual transaction use established estimation techniques option pricing models estimated discounted values cash flows fair values balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either heldfortrading availableforsale heldtomaturity originated group heldfor trading financial assets acquired principally generate profit shortterm fluctuations inprice heldtomaturity financial assets securities fixed maturity group intent ability hold maturity financial assets originated group loans andother longterm financial assets created group acquired issuer primary market financial assets considered availableforsale financial assets initially recorded cost including transaction costs purchases sales recognised settlement date heldfortrading financial assets subsequently carried fair value changes fair value recorded financial income expense period arise heldtomaturity financial assets subsequently carried amor tised cost using effective interest rate method availableforsale financial assets subse quently carried fair value unrealised changes fair value recorded equity availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income expense current period financial assets originated group subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty december group revised accounting policy impairment financial assets addition impairment triggers availableforsale financial assets market value original cost sustained sixmonth period considered impaired falls market price less original cost orfor less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity isobjective evidence impairment asset sold otherwise disposed notes consolidated financial statements derivatives derivative financial instruments initially recorded cost including transaction costs derivatives subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value arerecorded financial income expense period arise hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing offuture cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions ondocumentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting inthis case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income expense qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining inef fective portion reported financial income expense hedging relationship hedge firm commitment highly probable forecasted transaction cumulative changes fair value hedging instrument recorded equity included initial car rying value asset liability time recognised qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income expense time forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income expense hedging instrument derivative equity cases entity disposed cumu lative changes fair value hedging instrument recorded equity included financial income expense time disposal international financial reporting standards revised new standards interpretations became effective january significant effect groups financial statements notes consolidated financial statementschanges effective january several revised new standards interpretations became effective january theprincipal item affecting group standard financial instruments recognition measurement implementing changes resulted increase equity million swiss francs effective january included comparative opening balances consolidated financial statements changes fully described consolidated financial statements future developments international financial reporting standards international financial reporting standards continue develop coming years theinternational accounting standards board published several exposure drafts however atthe time ofpublication financial statements new standards adopted thatwould need applied financial risk management financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt group companies report details financial instruments outstanding financial liquidity group treasury least monthly basis new post financial risk manager created oversee compliance groups financial risk management policies guidelines policies group accordance risk management guidelines continues monitor risks deemed appropriate certain risks significantly altered use financial instruments derivatives group management believes order create optimum value group desirable eliminate mitigate possible market fluctuations foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs group continues monitor currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts foreign currency options optimise certain anticipated foreign exchange revenues cash flows financing transactions transaction exposure arises amount local currency paid received trans actions denominated foreign currencies may vary due changes exchange rates many group companies income primarily local currency significant amount expendi ture especially purchase goods resale interest repayment loans foreign currencies similarly transaction exposure arises net balances monetary assets held foreign currencies group companies manage exposure local level necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure help comprehensive data received monthly basis notes consolidated financial statements translation exposure arises consolidation foreign currency denominated finan cial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group hedges significant net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regular basis significant part groups cash outflows research development production admin istration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc rela tive currencies adverse impact consolidated net income similarly relative fall value swiss franc favourable effect results published swiss francs interest rate risk interest rate risk arises movements interest rates could adverse effects thegroups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk interest rates groups major debt instruments fixed asdescribed note reduces groups exposure changes interest rates group companies manage shortterm interest rate risk local level necessary using financial instruments interest rate forward contracts swaps options market risk changes market value certain financial assets liabilities instruments affect net income financial position group longterm investments held strategic pur poses marketable securities held fund management purposes risk loss value reduced reviews prior investing concentration investments continuous monitoring performance investments changes risk configuration investments equity fixed income instruments entered basis approved guidelines regard liquidity credit rating credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focussing assessment country risk credit availability ongoing credit evaluation account monitoring procedures signifi cant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread country risk limits exposures continuously monitored exposure financial assets credit risk controlled set ting policy limiting credit exposure highquality counterparties ongoing reviews credit ratings limiting individual aggregate credit exposure accordingly notes consolidated financial statementsliquidity risk group companies need sufficient availability cash meet obligations individual companies responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group allows make efficient use international capital markets financing purposes group organisation overview subsidiaries associated companies included pages changes group organisation chugai chugai alliance discussed note vitamins fine chemicals division demerger vitamins fine chemicals division discussed note antisoma investment antisoma treated associated company discussed note changes group organisation amira november group acquired share capital amira medical inc amira amira company active diabetes monitoring based united states netconsideration paid million swiss francs allocated follows net assets acquired millions chf goodwill intangible assets deferred income taxes provisions net assets liabilities total notes consolidated financial statements segment information millions chf divisional information roche genentech japan prescription prescription prescription otc segment revenues segment revenuedivisional sales less interdivisional sales divisional sales third parties segment resultsoperating profit segment assets liabilities divisional assets segment assets segment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segment information capital expenditure depreciation amortisation impairment longterm assets research development costs major legal cases vitamin case share result associated companies investments associated companies number employees group three divisions pharmaceuticals diagnostics vitamins fine chemicals disclosure pharmaceuticals division includes four reportable segments roche prescription genentech prescription japan prescription otc japan prescription business segment includes results newly merged chugai company includes former nippon roche business october also includes results nippon roche periods september nippon roches results reclassified segment roche prescription segment japan prescription see note results chugais otc business included japan prescription business segment vitamins fine chemicals division process demerged considered noncore business see note segment others consists costs corporate headquarters costs reasonably attributed reported segments notes consolidated financial statementstotal core vitamines pharmaceuticals diagnostics others businesses fine chemicals group transfer prices interdivisional sales set arms length basis divisional assets consist primarily property plant equipment goodwill intangible assets receivables inventories divisional liabili ties consist trade accounts payable segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assets liabilities provisions nonsegment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments associated companies investments debt capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions notes consolidated financial statements geographical information sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total segment assets include property plant equipment goodwill intangible assets receivables inventories trade accounts payable assets reasonably attributed reported geographical segments nonsegment assets mainly include current deferred income tax balances financial assets principally cash marketable securities investments associated companies investments capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions genentech effective september group acquired majority interest approximately genentech inc biotechnology company united states june group exer cised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock result notes consolidated financial statementsof groups majority interest genentech issues additional shares common stock connection equity compensation plans also may issue additional shares purposes affiliation agreement group genentech provides amongst things genentech establish stock repurchase programme maintain groups percentage ownership interest genentech december groups interest genentech common stock genentech publicly traded listed new york stock exchange symbol dna genentech incorporated delaware principal executive offices south san francisco california market capitalisation december billion us dollars billion swiss francs genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone results us gaap basis results genentech consolidated roche group accordance ifrs reconciled table usd chf usd chf millions millions millions millions net income us gaap basis add back nonoperating items us gaap basis change us gaap accounting policies income taxes net financial income add deduct ifrs vs us gaap differences consolidation entries amortisation goodwill capitalised iprd amortisation goodwill goodwill differences consolidation entries add back us gaap litigation charges deduct litigation charges ifrs basis segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income expense net income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis operating profit ifrs basis excluding litigation charges net income ifrs basis excluding litigation charges impairment financial assets income applicable minority interest ifrs basis excluding litigation charges impairment financial assets notes consolidated financial statements differences ifrs us gaap following acquisition group interest genentech june analy sis carried acquisition accounting identified total million us dollars attributable inprocess research development iprd genentechs us gaap financial statements items recorded either adjustment equity onetime expense ifrs items classified separate assets date acquisition therefore form part goodwill therefore years subsequent goodwill amortisation expense respect iprd groups results ifrs genentech adopted us accounting standards fas fas effective january goodwill longer amortised subject impairment test least annually ifrs goodwill continues amortised also subject testing impairment genentech stock repurchases stock options october genentechs board directors authorised stock repurchase programme torepurchase million us dollars genentechs common stock august genentechs board authorised extension repurchase additional million com mon stock genentech repurchased million us dollars million swiss francs common stock common stock worth million us dollars million swiss francs repurchased includes million us dollars million swiss francs thatwas repurchased prior october genentech stock option plan adopted amended plan allows thegranting various stock options stock awards stock appreciation rights employees directors consultants genentech movements number options held genentech employees follows outstanding january issued exercised cancellations outstanding end period exercisable options issued year average exercise price usd optionsexercised year exercised average price usd cash inflow genentech stock option employee stock plans million us dol lars million swiss francs million us dollars million swiss francs using blackscholes option valuation model fair value options issued million us dollars million swiss francs million us dollars million swiss francs net accounting effect stock repurchases stock options recorded minority interests see note matters discussed note group recorded provision million us dollars million swiss francs respect certain litigation matters including litigation involving city hope january group issued lyons iv zero coupon us dollar notes exchange able genentech shares notes converted groups percentage owner ship genentech would decrease approximately see also note notes consolidated financial statements chugai december roche chugai announced would enter alliance create leading researchdriven japanese pharmaceutical company would formed merger chugai excluding genprobe roches japanese pharmaceuticals subsidiary nippon roche terms alliance chugai nippon roche inde pendently valued roche agreed make additional cash contributions order bring roches participation agreed combined value alliance approved share holders chugai annual general meeting june newly merged company known chugai fully consolidated subsidiary group roche majority shareholder ownership minority interest chugai domiciled tokyo listed tokyo stock exchange market capitalisation december billion japanese yen billion swiss francs transaction process lateseptember roche acquired public tender offer approximately mil lion shares chugais outstanding shares price jpy per share total cash outflow group result tender offer billion japanese yen million swiss francs immediately tender offer roche subscribed issue chugai million new shares price jpy per share resulted cash contribution tochugai billion japanese yen million swiss francs september closing tender offer roche chugai completed spinoff shareholdings ingenprobe californiabased diagnostics subsidiary registered shareholders july october chugai merged nippon roche prior merger nippon roche issued convertible bonds roche group roche cb obligation succeeded chugai october roche acquired additional shares chugai conversion bonds pro portion shares issued chugai conversion convertible bonds previously issued chugai third parties chugai cb roches ownership reached resulted cash contribution billion japanese yen million swiss francs ongoing basis roche convert remaining roche cb chugai shares corresponding conversion remaining chugai cb roche maintains ownership chugai purchase consideration closing transaction october transaction accounted using purchase method accounting consideration paid roche chugai consists firstly public tender offer secondly subscription new chugai shares con version roche cb relates minority shareholders thirdly net assets nippon roche attributable minority shareholders nippon roche public company net assets nippon roche valued reference fair value chugai shares acquired exchange allocation shown table jpy billions chf millions public tender offer subscription billion jpy convertible bonds billion jpy implied value nippon roche transaction costs purchase consideration chugai notes consolidated financial statements acquisition accounting market value chugai shares acquired billion japanese yen million swiss francs corresponds market capitalisation chugai prior transaction purchase consideration billion japanese yen million swiss francs therefore represents surplus billion japanese yen million swiss francs market value chugai shares acquired surplus writtenoff recorded net assets chugai exceed market capitalisation result transaction gain billion japanese yen million swiss francs arises part disposal nippon roche accordingly net income billion yen million swiss francs wasrecognised theincome statement two amounts acquired net assets chugai shown table amount allocated good includes billion japanese yen million swiss francs attributable inprocess research development international financial reporting standards items classified separate assets date acquisition therefore form part goodwill net assets acquired jpy billions chf millionsa property plant equipment goodwill intangible assets inventories deferred income taxes liabilities postemployment benefits provisions net assets liabilities minority interests total translated september exchange rate jpy chf ongoing impacts purchase accounting october chugais results included groups consolidated financial state ments japan prescription shown separate business segment segment information japan prescription business segment includes results newly merged chugai company includes former nippon roche business october also includes results nippon roche periods september comparability nippon roches results reclassified segment roche prescription tothe segment japan prescription results chugais otc business included japan prescription business segment segment information given note fair value adjustments arising acquisition accounting following impacts groups financial statements th quarter onwards jpy chf jpy chf jpy chf billions millions billions millionsa billions millionsa writeoff fair value adjustments inventories depreciation property plant equipment amortisation acquired intangible assets amortisation goodwill impact operating profit deferred income taxes impact net income translated december exchange rate jpy chf notes consolidated financial statementsthe fair value adjustments inventories fully writtenoff line inventory turnover end first quarter goodwill acquired intangible assets amortised straightline basis years years respectively pharmaceuticals division restructuring millions chf may group announced reshaping future growth initiative restructur ing pharmaceuticals division objective improving longterm profitability division increasing sales reducing divisions cost structure activity year shown table significant additional costs expected restructuring expenses impairment property plant equipment employee costs closure costs curtailment gain postemployment plans total restructuring expenses restructuring provision january additional provisions created unused amounts reversed amounts utilised currency translation effects december vitamins fine chemicals division millions chf early group announced plans demerge vitamins fine chemicals division september group announced reached agreement subject execution final definitive purchase agreement necessary regulatory approvals sell global vitamins fine chemicals business dutch company dsm final purchase agreement signed february sale expected close first half expected transaction price billion euros consist billion euros cash million shares dsm value approximately million euros december exchange rates billion euros equivalent billion swiss francs vitamins fine chemicals division treated discontinuing operation however sale closed continue included consolidated figures sales results assets liabilities net cash flows division part roche group shown discontinuing operations following table notes consolidated financial statements continuing operations discontinuing operations group statement income sales third parties expenses impairment net assets operating profit financial income expense net impairment financial assets profit taxes income taxes profit taxes minority interests share result associated companies net income balance sheet december property plant equipment intangible assets longterm assets current assets total assets longterm debt noncurrent liabilities current liabilities total liabilities net assets statement cash flows operating activities financing activities investing activities net effect currency translation cash increase decrease cash impairment net assets based final agreement group management estimates current carrying value net assets vitamins fine chemicals business excess expected net proceeds sale accordingly impairment million swiss francs recorded assets vitamins fine chemicals division addition tax expenses million swiss francs recorded based upon preliminary estimate tax liability arise disposal sale close first half final amount gain loss thedisposal ofthe net assets vitamins fine chemicals business including tax effects maybe different amounts currently recorded notes consolidated financial statementsvitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suitbrought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately december based development litigation recent settlement negotiations group recorded additional provisions million swiss francs december group reassessed adequacy remaining provisions vitamin case based development litigation recent settlement negotiations mainly united states direct customers previously opted class action settlement group recorded additional provisions million swiss francs total payments year million swiss francs million swiss francs payments made include fines imposed european union totalling million euros million swiss francs settlements direct indirect customers united states totalling million us dollars million swiss francs group seeking resolve remaining outstanding issues however timing final amounts involved uncertain provisions recorded based current litigation recent settlement agreements litigation negotiations progress possible ultimate liability may different amount provisions currently recorded january district columbia circuit court appeals ruled nonus plaintiffs may bring claims us courts us antitrust laws alleged damages suffered transactions outside united states connection vitamin case defendants including roche appeal decision provisions recorded respect ofthis litigation eventual outcome uncertain stage part demerger process liabilities respect vitamin case remain theroche group roche dsm signed indemnity cooperation agreement roche may provide dsm certain indemnities guarantees connection vitamin case major legal cases developments year major legal cases discussed including impact groups results possible future development contingent liabilities total expenses year million swiss francs respect genentech legal cases igen litigation february united states district court maryland entered judgement civil litigation roche diagnostics gmbh germany rdg igen international inc igen claims related licensing igens electrochemiluminescence ecl rdg court concluded several breaches licence agreement material igen right terminate licence agreement awarded igen million us dollars compensatory damages million us dollars punitive damages rdg appealed judge ment final resolution expected second half existing order court bars licence termination appeal proceedings completed whileany appeal progress rdg continue provide customers products andservices continue planned innovations based ecl technology notes consolidated financial statements rdg previously boehringer mannheim litigation since matters acquiring boehringer mannheim rdg assessed igen litigation adequacy provision already recorded boehringer mannheim rdg reassessed adequacy provisions concluded based currently available information appropriate record additional provisions point total amount provisions liability rdg expects pay adjusted foreign currency translation effects time value money litigation process possible final obligation may different total amount provisions disclosed may prejudice rdg position current litigation however provisions significantly less amounts awarded court march roche diagnostics gmbh rdg paid million us dollars million swiss francs collateral deposit account respect igen litigation reported restricted cash within financial longterm assets see note additional provisions recorded year genentech legal cases group recorded provision million us dollars million swiss francs respect certain litigation matters including litigation involving city hope june genentech announced los angeles county superior court jury voted award city hope medical center approximately million us dollars compensatory dam ages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal appeals process take one four years depending scope review full provision recorded awards appeals process interest accrues total amount damages simple annual rate following judgment interest million us dollars million swiss francs recorded time cost provisions within interest expenses see note october genentech entered arrangement third party insurance companies post surety bond million us dollars connection judgement part arrangement genentech pledged million us dollars cash andinvestments secure bond amounts equivalent million swiss francs reported restricted cash within financial longterm assets see note addition genentech party patent infringement suit filed chiron corporation june us district court eastern district california sacramento respect herceptin june court issued several decisions regarding summary judgement motions filed jury trial suit began august following first phase trial based findings jury court entered judgement favour genentech november chiron filed notice appeal us court appeals federal circuit december genentech filed notice crossappeal court august united states patent trademark office declared interference chiron patent involved lawsuit patent application exclusively licensed togenentech university pennsylvania relating antiher antibodies declaring interference patent office determined substantial question whether inventors chiron patent first invent technology involved entitled patent connection second patent infringement lawsuit filed march genentech chiron discovery case currently stayed notes consolidated financial statementsin connection patent infringement lawsuit filed genentech glaxosmithkline glaxo september september genentech glaxo agreed settlement pursuant genentech glaxo dismissed prejudice claims andor counter claims made lawsuit previous patent infringement lawsuit filed genentech glaxo may involving patents settlement resolves ends patent infringement claims glaxo made genentech genentech party litigation described genentechs annual report quarterly sec filings however matters far advanced matters referred employee benefits millions chf wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans employee benefits total employees remuneration charges employee benefits included relevant expenditure line function number employees yearend employee benefits consist mainly life insurance schemes certain insurance schemes providing medical dental cover postemployment benefits employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic con ditions countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states plans usually funded payments group employees trusts inde pendent groups finances plan unfunded liability whole obligation recorded groups balance sheet amounts recognised arriving operating profit postemployment defined benefit plans follows current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment total included employees remuneration actual return plan assets negative return million swiss francs negative return million swiss francs september group paid additional contribution million us dollars mil lion swiss francs postemployment defined benefit plan one us subsidiaries due falls market value plans assets payment included contri butions paid table accounted part recognised surplus funded pension plans see also note groups consolidated financial statements beincluded actuarial calculation groups pension expenses balances notes consolidated financial statements movements net asset liability recognised balance sheet postemployment defined benefit plans follows beginning year chugai total expenses included employees remuneration contributions paid benefits paid unfunded plans reclassification prepaid employee benefits currency translation effects end year amounts recognised balance sheet postemployment defined benefit plans follows funded plans actuarial present value funded obligations due past present employees plan assets held trusts fair value plan assets excess deficit actuarial present value funded obligations unrecognised actuarial gains losses unrecognised past service costs net recognised asset liability funded obligations due past present employees unfunded plans recognised liability actuarial present value unfunded obligations total recognised asset liability funded unfunded obligations due past present employees reported surplus recognised part longterm assets deficit recognised part liabilities postemployment benefits total net asset liability recognised amounts include nonpension postemployment benefit schemes principally medical plans follows actuarial present value obligations due past present employees plan assets held trusts fair value plan assets excess actuarial present value funded obligations less unrecognised actuarial gains losses net recognised asset liability amounts recognised balance sheet postemployment defined benefit plans pre dominantly noncurrent reported longterm assets noncurrent liabilities included within fair value assets funded plans groups nonvoting equity securities fair value million swiss francs million swiss francs notes consolidated financial statementsthe group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used theactuarial valuations significant defined benefit plans countries withstable currencies interest rates follows discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate stock appreciation rights employees certain us subsidiaries group receive stock appreciation rights sars part compensation sars may exercised vesting period two tothree years cash payment based upon amount market price groups american depositary shares adss point exercise exceeds strike price grant priceat issuance group accrues expected cash outflow outstanding sars december accrual required equity compensation benefits group launched three equity compensation plans described thegenentech stock option plan discussed note roche option plan group offers nonvoting equity security options certain directors management exercise price market price nonvoting equity securities date issue options nontradable sevenyear duration vest phased basis three years group covers obligations purchasing nonvoting equity secu rities derivatives thereon cost instruments reported equity instruments within equity balance sheet options exercised cash received credited equity instruments impacts income statement employer social insurance costs administrative costs plan previous option compensation plan whereby group purchased options directly third party financial institutions granted certain employees closed existing option grants old plan continue options granted movements number options held employees follows outstanding january issued exercised cancellations outstanding december details options granted period follows issue date february expiry date february exercise price chf proceeds options exercised millions chf using blackscholes option valuation model fair value options issued million swiss francs notes consolidated financial statements roche performance share plan group offers future nonvoting equity security grants certain directors key senior management amount nonvoting equity securities granted depends upon individuals salary level achievement performance targets linked total shareholders return relative groups peers threeyear period date grant targets met grants made grants vest three years cost plan accrued vesting period grant based final cash outflow estimated balance sheet date year cost plan million swiss francs reported within relevant operating expense categories group covers obligations purchasing nonvoting equity securities derivatives thereon cost purchasing instruments reported equity instruments within equity balance sheet roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group makes contribution programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary non voting equity securities directly market nonvoting equity securities held december programme operational since october year cost plan million swiss francs reported within relevant operating expense categories operating income expense net millions chf royalty income gain disposal neupogen operating income total operating income royalty expense operating expense total operating expense total operating income expense net october group completed sale amgen assets business related toneupogen european union switzerland norway cash received million swiss francs notes consolidated financial statements financial income expense net millions chf gains sale equity securities losses sale equity securities gains labcorp transactions dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities writedowns impairments longterm loans net interest income income debt securities interest expense amortisation discount debt instruments gains losses interest rate derivatives net time cost provisions net interest expense foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense net total financial income expense net june group sold shares labcorp resulting pretax gain incidental costs million swiss francs recorded part financial income expense net net pretax cash inflow million swiss francs date sale groups remaining investment labcorp accounted availableforsale marketable securities march july group sold remaining shares labcorp transactions resulted pretax gain incidental costs million swiss francs amounts recorded part financial income expense net net pretax cash inflow million swiss francs addition group realised gain million swiss francs equity derivatives entered connection disposal labcorp shares december group remaining ownership interest labcorp outstanding derivative positions labcorp equities impairment financial assets december group revised accounting policy impairment financial assets addition existing impairment triggers described note availablefor sale financial assets market value original cost sustained six month period considered impaired falls market price less original cost less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed notes consolidated financial statements result revision accounting policy group recorded impairment charge million swiss francs effective december income taxes millions chf income tax expenses amounts charged income statement follows current income taxes deferred income taxes total charge income taxes since group operates across world subject income taxes many different tax juris dictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate increased operating income makes considerably higher proportion pretax income case previous years leads increase groups effective tax rate operating income typically occurs jurisdictions higher tax rates compared financial income within groups average expected tax rate increasing significance genentech chugai accounts increase rate deferred tax assets recorded local statutory losses incurred argentina clear may utilised future local taxable income groups effective tax rate reconciled groups average expected tax rate follows groups average expected tax rate tax effect argentina amortisation goodwill gain sale labcorp shares nontaxable incomenondeductible expenses differences core businesses effective tax rate tax effect pharmaceuticals division restructuring major legal cases discontinuing operation vitamins fine chemicals division vitamin case chugai transaction part disposal nippon roche chugai transaction writeoff fair value adjustments inventories vitamins fine chemicals division impairment net assets impairment financial assets groups effective tax rate impairment net assets vitamins fine chemicals division impairment offinancial assets significant impact effective tax rate alarge impact profit tax whilst relatively minor impact tax charge notes consolidated financial statementsincome tax assets liabilities amounts recognised balance sheet income taxes follows current income taxes current income tax assets current income tax liabilities net current income tax asset liability balance sheet deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability balance sheet increase current income tax assets related payments vitamin case swiss withholding taxes subsequently reimbursed deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses million swiss francs deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year charged credited income statement charged credited equity chugai currency translation effects net deferred income tax asset liability end year net deferred income tax asset liability beginning year issue debt instruments charged credited income statement charged credited equity changes group organisation currency translation effects net deferred income tax asset liability end year notes consolidated financial statements property plant equipment millions chf buildings land machinery improve construction land ments equipment progress total total net book value beginning year chugai changes group organisation genentech synthetic leases additions disposals transfers depreciation charge pharmaceuticals division restructuring impairment charge vitamins fine chemicals division impairment net assets impairment charges currency translation effects end year december cost accumulated depreciation net book value groups subsidiary genentech synthetic leases certain facilities california groups accounting policy consolidated discussed financial statements recorded effective january date property plant equipment increased million swiss francs similar increase longterm debt seenote excluding genentech synthetic leases december capitalised cost machinery equipment finance leases amounts million swiss francs million swiss francs net book value assets amounts million swiss francs million swiss francs operating lease commitments december future minimum annual payments noncancellable operating leases including genentech synthetic leases follows within one year one five years thereafter total minimum annual payments total rental expense operating leases including genentech synthetic leases million swiss francs million swiss francs group capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs notes consolidated financial statements intangible assetsin millions chf patents licences trademarks goodwill total total net book value beginning year chugai changes group organisation additions disposals amortisation charge vitamins fine chemicals division impairment net assets impairment charge currency translation effects end year december cost accumulated amortisation end year investments associated companies joint ventures millions chf associated companies group investments associated companies listed accounted using equity method share net income balance sheet value laboratory corporation america holdings usa basilea pharmaceutica switzerland investments accounted using equity method total investments accounted using equity method laboratory corporation america holdings groups transactions labcorp shares discussed note december group remaining ownership interest labcorp basilea pharmaceutica group owns noncontrolling interest basilea pharma ceutica ltd basilea basilea swiss biotechnology company antibacterial antifungal dermatology fields basilea private company domiciled basel share capital million swiss francs december antisoma december group acquired interest antisoma plc antisoma million swiss francs antisoma british biopharmaceutical company develops products treatment cancer public company domiciled london shares traded london stock exchange nasdaq europe market capitalisation asat december million pounds million swiss francs following acqui sition group material transactions antisoma access development milestone payments respect oncology product portfolio accordingly antisoma reported associated company million swiss francs goodwill arose acquisition balance acquisition price reported investment associated companies notes consolidated financial statements transactions group associated companies follows income statement income sale goods supply services expenses purchase goods supply services balance sheet trade accounts receivable joint ventures bayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve andcertain otc products united states joint venture private company regis tered delaware principal executive offices morristown new jersey partnership capital million us dollars million swiss francs december joint venture included financial statements using proportionate consolidation method chugaiaventis joint venture chugai pharma marketing ltd whollyowned subsidiary chugai stake chugaiaventis snc joint venture aventis pharma sa forimportation sales pharmaceuticals clinical development submission application new drugs eu joint venture partnership domiciled antony france hada share capital thousand euros thousand swiss francs december thejoint venture included financial statements using proportionate consolidation method effect groups joint ventures income statement balance sheet follows income statement sales expenses net income taxes balance sheet longterm assets current assets noncurrent liabilities current liabilities net assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets financial longterm assets held strategic purposes therefore classified noncurrent effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year notes consolidated financial statementsrestricted cash consists million us dollars paid collateral deposit account respect igen litigation see note million us dollars cash investments pledged genen tech connection city hope litigation see note million swiss francs pledged roche group companies collateral connection obligation repurchase equity instruments see note cash set aside collateral certain lease agreements longterm assets millions chf recognised surplus funded pension plans prepaid employee benefits total longterm assets longterm assets consist various assets otherwise shown separately thegroup expects derive economic benefits one year inventories millions chf raw materials supplies work process finished goods less provision slowmoving obsolete inventory total inventories inventories held net realisable value carrying value million swiss francs million swiss francs result chugai transaction inventories increased million swiss francs effective october see note accounts receivable millions chf accounts receivable trade notes receivable less provision doubtful accounts total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs bad debt expense million swiss francs million swiss francs current assets millions chf accrued interest income prepaid expenses derivative financial instruments receivables total current assets notes consolidated financial statements marketable securities millions chf heldfortrading investments bonds debentures availableforsale current investments shares bonds debentures money market instruments total marketable securities marketable securities held fund management purposes therefore classified ascurrent investments held strategic purposes classified noncurrent seenote shares consist primarily readily saleable equity securities bonds debentures average effective contracted maturity amount interest rate within one year one five years five years total bonds debentures within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december accounts payable millions chf accounts payable trade taxes payable accounts payable total accounts payable accrued current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities notes consolidated financial statements equity share capital annual general meeting april shareholders approved stock split shares nonvoting equity securities roche holding ltd split took place may number shares nonvoting equity securities issue respectively nominal value shares swiss franc non voting equity securities nominal value per share information restated split took place january based information supplied roche shareholders group pooled voting rights comprising dr l hoffmann ms v michalskihoffmann ms hoffmann mr hoffmann msv oerihoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeri dr f gerber group holds shares share split preceding year figure include shares without pooled voting rights held outside group individual members group transactions individuals ordinary course business nonvoting equity securities genussscheine december nonvoting equity securities issued swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company isentitled times exchange nonvoting equity securities shares participation certificates dividends april shareholders approved distribution dividend swiss francs per share nonvoting equity security swiss franc respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings equity instruments december number nonvoting equity securities held net cash inflow transactions equity instruments million swiss francs net cash inflow million swiss francs group holds equity instruments primarily meet obligations may arise respect certain groups debt instruments may achieved holding physical nonvoting equity securities holding forward contracts derivative instruments call options december group held forward contracts derivative instruments equivalent nonvoting equity securities contracts instruments exercised total nonvoting equity securities would available group notes consolidated financial statements group partially covered exposure conversion sumo japanese yen exchangeable bonds fully covered exposure lyons v zero coupon us dollar exchangeable notes achieved using written short put options purchased long call options strike price combined effect forward purchase commitment million swiss francs repurchase nonvoting equity securities reported within debt discounted present value million swiss francs see note transactions supported million swiss francs collateral recorded restricted cash financial longterm assets see note earnings per share nonvoting equity security per share information restated share split took place may see note basic earnings per share nonvoting equity security net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions total millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security weighted average number shares nonvoting equity securities outstanding adjusted assume conversion dilutive potential shares nonvoting equity securities net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions weighted average number shares nonvoting equity securities issue used calculate dilutive earnings per share millions diluted earnings per share nonvoting equity security chf notes consolidated financial statements fair value reserves millions chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investments hedges options reserve total total beginning year changes fair value recognised net income deferred income taxes minority interests equity component new convertible debt currency translation gains losses total minority interests millions chf beginning year chugai part disposal nippon roche minority share group net income net tax net effect movements fair value charged credited equity net effect exercise genentech stock options genentech stock repurchases dividend payments minority shareholders currency translation effects end year genentech chugai total minority interests debt millions chf amounts due banks financial institutions debt instruments capitalised lease obligations genentech synthetic leases obligation repurchase equity instruments borrowings total debt less current portion longterm debt amounts due within one year total longterm debt shortterm bank loans overdrafts current portion longterm debt total shortterm debt notes consolidated financial statements repayment terms longterm debt within one year one two years two three years three four years four five years thereafter total longterm debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value debt instruments billion swiss francs billion swiss francs fair value total longterm debt billion swiss francs billion swiss francs calculated based upon present value future cash flows instru ment discounted market rate interest instruments similar credit status cash flowsand maturity periods groups debt unsecured except noted obligation arising genentech synthetic leases supported restricted cash million us dollars million swiss francs addition obligation secured property plant equipment covered synthetic leases net book value million swiss francs december obligation repurchase nonvoting equity securities supported million swiss francs ofcollateral recorded restricted cash financial longterm assets see note amounts due banks financial institutions interest rates amounts primarily denominated us dollars euros average approximately repayment dates vary years debt instruments repayment samurai japanese yen bonds due date may group repaid principal amount billion japanese yen japanese yen bonds originally issued resulting cash outflow million swiss francs japanese yen convertible bonds issued chugai december chugai standing series chugai pharmaceutical unsecured convertible bonds principal amount million japanese yen million swiss francs bonds issued face value redemption date september bond jpy par value convertible shares chugai conversion option bondholder may made time due date bonds redeemable maturity repayment bull spread us dollar bonds due date may group repaid principal amount billion us dollars ofthe us dollar bonds originally issued resulting cash outflow million swiss francs issue lyons v us dollar exchangeable notes july group issued zero coupon us dollar exchangeable notes due july aprincipal amount million us dollars net proceeds issue million us dollars million swiss francs initially allocated million swiss francs debt million swiss francs unamortised discount million swiss francs equity respect conversion option embedded bonds million swiss francs ofdeferred tax liability notes consolidated financial statementsthe carrying value groups debt instruments given table effective interest rate swiss franc bonds bullet due principal billion swiss francs rodeo due principal billion swiss francs us dollar bonds chameleon due principal billion us dollars japanese yen bonds samurai due principal billion japanese yen swiss franc convertible bonds helveticus dividendlinked convertible bonds due principal billion swiss francs zero coupon us dollar exchangeable notes lyons ii due principal billion us dollars lyons iii due principal billion us dollars lyons iv due principal billion us dollars lyons v due principal billion us dollars japanese yen exchangeable bonds sumo due principal billion japanese yen limited conversion preferred stock japanese yen convertible bonds issued chugai total debt instruments swiss franc convertible bonds helveticus annual payment distribution amount paid july bond chf par value place fixed rate interest annual payment distribution amount equals two hundred times ordinary andor extraordinary dividend declared one nonvoting equity security roche holding ltd business year ended december nineteen months prior july relevant year bond exchangeable one hundred nonvoting equity securities roche holding ltd time life bond accordance terms bonds additional cash payment chf made upon conversion bond zero coupon us dollar exchangeable notes lyons ii notes exchangeable american depositary shares adss adjusted exchange ratio exchange adss per usd principal amount maturity notes group purchase note cash option holder april purchase price per usd principal amount notes usd addition notes redeemable option group whole part time april issue price plus accrued original issue discount oid notes consolidated financial statements lyons iii notes exchangeable adss exchange ratio exchange adssper usd principal amount maturity notes group purchase notefor cash option holder may may purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time may issue price plus accrued original issue discount oid lyons iv notes exchangeable genentech shares exchange ratio genentech shares per usd principal amount maturity notes group right pay cash equal market value genentech shares lieu delivering genen tech shares group purchase note cash option holder january january purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time january issue price plus accrued original issue discount oid lyons v notes exchangeable adss exchange ratio exchange adssper usd principal amount maturity notes group purchase note cash option holder january july july apurchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group inwhole part time july issue price plus accrued original issue discount oid japanese yen exchangeable bonds sumo bond jpy par value exchangeable one hundred nonvoting equity securities roche holding ltd exchange ratio bonds redeemable maturity issue price plus accrued original issue discount oid unamortised discount included within carrying value debt instruments following unamortised discounts swiss franc bonds us dollar bonds japanese yen bonds swiss franc convertible bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount derivative financial instruments millions chf appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value methods used determining fair value described note notes consolidated financial statements foreign currency derivatives forward exchange contracts swaps options interest rate derivatives swaps derivatives total carrying value derivative financial instruments asset liability recognised current assets accrued current liabilities total net asset liability recognised hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropri ate certain risks altered use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instru ment hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense due considerable administrative cost maintaining necessary documentation tracking procedures group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described groups subsidiary genentech also described genentechs annual report quarterly sec filings genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part expo sure genentech enters derivative financial instruments zero cost collars forward contracts genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part transaction exposure genentech enters derivative financial instruments options forward contracts genentech also anticipated cash flows interestbearing investments exposed changes interest rates manage part risk genentech enters interest rate swap agreements effectively convert part expected interest income vari able fixed rate swaps terminated determined fore casted transaction unlikely occur gain million us dollars million swiss francs recognised financial income expense movements fair value reserve designated cash flow hedges included note notes consolidated financial statements provisions millions chf restructuring provisions provisions total total beginning year chugai changes group organisation pharmaceuticals division restructuring additional provisions created unused amounts reversed utilised year vitamin case additional provisions created utilised year major legal cases additional provisions created utilised year provisions additional provisions created unused amounts reversed utilised year increase discounted amount due passage time change discount rate currency translation effects end year current portion provisions noncurrent portions provisions total provisions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated theongoing activities group creation provisions recorded charge operating income except arise restructuring newly acquired companies case included acquisition accounting hence form part ofthe goodwill see also note regarding pharmaceuticals division restructuring provisions consist mainly legal environmental similar matters provisions include provisions respect vitamin case see note major legal cases see note contingent liabilities operations earnings group continue time time varying degrees tobe affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency developments events covered insurance well effecton future operations earnings predictable see also note respect vitamin case note respect major legal cases notes consolidated financial statements cash flow statement millions chf cash flows operating activities cash flows operating activities derived groups primary activities asdescribed divisional review calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including example taxes paidon gains labcorp share sales net income add back nonoperating income expense financial income expense net impairment financial assets income taxes income applicable minority interests share result associated companies operating profit depreciation property plant equipment amortisation intangible assets impairment longterm assets changes group organisation chugai transaction writeoff fair value adjustments inventories charge pharmaceuticals division restructuring charge vitamin case charge major legal cases expense defined benefit postemployment plans adjustments cash generated operations cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity proceeds issue longterm debt lyons v zero coupon exchangeable us dollar notes due longterm bank loans borrowings total repayment longterm debt repayment samurai japanese yen bonds repayment bull spread us dollar bonds longterm bank loans borrowings total notes consolidated financial statements interest dividends paid interest paid dividends paid total cash flows investing activities cash flows investing activities principally arising groups investments inproperty plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment itsoperating assets cash flow effects changes group organisation well cash generated groups investments cash flows marketable securities including income capital gains losses shownas net movement groups portfolio consist alarge number positions held longterm basis cash flows labcorp transactions see note shown separate line cash flow statement cash flows respect chugai consist cash payments roche third parties less cash held chugai acquired acquisitions subsidiaries associated companies products chugai antisoma amira acquisitions total divestments subsidiaries associated companies products neupogen divestments total interest dividends received interest received dividends received total subsequent events acquisition disetronic february roche disetronic announced plans group would acquire disetronic disetronic world leader research development commercialisa tion insulin pumpsand injection systems treatment diabetes public company headquartered burgdorf switzerland completion acquisition disetronics infusion systems division become part roche diagnostics diabetes care business area group acquire disetronic injection systems sold disetronics founder chairman continue operate independent company group offer shareholders disetronic swiss francs cash two roche non voting equity securities disetronic share proposed acquisition subject approval competition authorities disetronics shareholders total cost theacqui sition expected approximately billion swiss francs expected proceeds resale injection systems division order million swiss francs notes consolidated financial statementsreport group auditors general meeting roche holding ltd basel auditors group audited consolidated financial statements roche group pages year ended december consolidated financial statements responsibility board directors roche holding ltd responsibility express opinion consolidated financial statements based audit confirm meet swiss legal requirements con cerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession international standards auditing require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstatement examined test basis evidence supporting amounts disclosures consolidated financial statements alsoassessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements roche group present fairly material respects financial position december results operations cash flows year ended accordance international financial reporting standards comply swiss law recommend consolidated financial statements submitted approved pricewaterhousecoopers ag william kirst clive aj bellingham basel february report group auditors multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income research development balance sheet millions chf longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf cash warrants addition dividend adjusted chf cash warrants addition dividend unadjusted chf information table stated reported changes accounting policy arising changes international financial reporting standards andthe stock split arenot applied retrospectively warrants held final exercise date b addition normal dividend shareholders approved share nonvoting equity security special ro centenary warrant worth chf date issue holders option cash equivalent chf c net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data multiyear overview c e f b e f warrants held final exercise date e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors multiyear overview sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours total sales geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overviewadditions property plant equipment division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overview roche securities share price performance chf roche share adjusted swiss market index rebased nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased american depositary receipt adr price performance usd roche adr adjusted sp index rebased one roche american depositary receipt adr equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july roche securitiesnumber shares nonvoting equity securitiesa number shares nominal value chf chf number nonvoting equity securities genussscheineno nominal value total data per share nonvoting equity securityc chf net income equity dividend e stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjusted shares yearend nonvoting equity securities genussschein yearend market capitalisation unadjusted millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares unadjusted priceearnings nonvoting equity securities genussscheine unadjusted nonvoting equity security genussschein confers rights shares participate avail able earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices stock price figures prior june adjusted effects givaudan spinoff adjustment factors used shares nonvoting equity securities factors used independent financial institutions c net income per share prior market capitalisation figures assume equity instruments held outstanding dividend include special dividend relating spinoff fragrances flavours division e dividend proposed board directors ticker symbols share nonvoting american equity security depositary receipt reuters roczs roczgs rohhypk bloomberg ro sw rog sw rohhy us swx swiss exchange ro rog roche securities outstanding issues summarised issue terms exchange terms warrants lyons ii april notes exchangeable american depositary shares face value usd adss adjusted exchange ratio exchange coupon zero adss per usd principal amount maturity notes issuer roche holdings inc exchange ratio changed accordance inden keep well roche holding ltd ture agreement dated april effective date exchange right roche adss may group purchase note cash roche call time april option holder april purchase price perusd principal amount notes usd inaddition notes redeemable option group whole part time april theissue price plus accrued original issue discount oid helveticus july bond chf par value exchangeable one hun face value chf dred nonvoting equity securities roche holding ltd coupon times ordinary andor time life bond accordance terms extraordinary dividend nonvoting bonds additional cash payment chf made upon equity securities genussscheine conversion bond chf par value issuer roche capital market international limited keep well roche holding ltd conversion right roche nonvoting equity securities genussscheine lyons iii may notes exchangeable american depositary shares face value usd adss exchange ratio exchange adss per coupon zero usd principal amount maturity notes exchange issuer roche holdings inc ratio changed accordance indenture agreement keep well roche holding ltd dated may effective date may exchange right roche adss group purchase note cash option holder roche call time may may may purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time may issue price plus accrued original issue discount oid rodeo march warrants expired unexercised march face value chf coupon issuer roche kapitalmarkt ag keep well roche holding ltd attached warrants roche nonvoting equity securities genussscheine bullet march face value chf coupon issuer roche international finance corporation limited keep well roche holding ltd roche securitiesoutstanding issues summarised issue terms exchange terms warrants chameleon july face value usd coupon issuer roche holdings inc keep well roche holding ltd lyons iv january notes exchangeable genentech shares face value usd exchange ratio genentech shares per usd coupon zero principal amount maturity notes group issuer roche holdings inc right pay cash equal market value genentech keep well roche holding ltd shares lieu delivering genentech shares group exchange right genentech common stock willpurchase note cash option holder roche call time january january january purchase price per usd principal amount notes usd andusd respectively addition notes redeemable option group whole part anytime january issue price plus accrued original issue discount oid sumo march bond jpy par value exchangeable one face value jpy hundred nonvoting equity securities roche holding ltd coupon exchange ratio bonds redeemable issuer roche holdings inc maturity issue price plus accrued original issue keep well roche holding ltd discount oid exchange right roche nonvoting equity securities genussscheine accordance terms bonds exchange ratio adjusted june may lyons v july notes exchangeable american depositary shares face value usd adss exchange ratio exchange adss per coupon zero usd principal amount maturity notes group issuer roche holdings inc purchase note cash option holder keep well roche holding ltd january july july pur exchange right roche adss chase price per usd principal amount notes roche call time july ofusd usd usd respectively inaddition notes redeemable option thegroup whole part time july attheissue price plus accrued original issue discount oid roche securities roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year financial statementsbalance sheet december millions chf longterm assets participations loans group companies total longterm assets current assets accounts receivable group companies accounts receivable prepaid expenses accrued income marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies liabilities accrued liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value financial statements notes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss company law accepted business principles valuation methods translation foreign currencies balance sheet assets liabilities disclosed net realisable values exceptions tothis rule participations shown acquisition values less appropriate writedowns marketable securities shown lower cost market value unrealised foreign currency gains balance sheet items deferred expenses income aswell foreign currency transactions translated exchange rates ruling relevant transaction dates details specific items income total income million swiss francs million swiss francs higher previous year mainly due better operating income taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity total equity equals total assets share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc nonvoting equity securities genussscheinewith nominal value guarantees guarantees favour group companies total million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible pledged assets assets total book value million swiss francs previous year pledged security companys commitments notes financial statementsparticipations major participations listed pages important shareholders shares company issued bearer reason company notkeep register shareholders following figures based information share holders shareholder validation check annual general meeting april onother information available company previous year shares shareholders group pooled voting rights comprising dr l hoffmann ms v michalskihoffmann ms hoffmann mr hoffmann msv oerihoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeri anddr f gerbera shares novartis international ltd basel including affiliates thereofb information supplied shareholders december figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel notes financial statements appropriation available earnings proposals general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account appropriation available earningsreport statutory auditors general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd basel forthe year ended december financial statements responsibility board directors responsibility toexpress opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession require audit planned performed manner obtain reasonable assurance whether financial statements free material mis statement examined test basis evidence supporting amounts disclosures inthe financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit pro vides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved ernst young ltd conrad lffel jrg zrcher basel february report statutory auditors arctic circle tropic cancer tropic capricorn roche ct ia rcrc letic global market presence sales switzerland manufacturing argentina research development australia toe lr lv mic ae ns u f fi ca tn uc rii nn gg third parties austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt el salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt ia rcrc letic guernsey south africa honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico vietnam morocco netherlands new zealand nicaragua norway pakistan panama peru philippines poland portugal puerto rico russia singapore roche global market presence subsidiaries associated companies group holds interest switzerlandf hoffmannla roche ltd basel roche vitamins canada inc cambridge ontario mostofthe companies listed exceptions chf roche ltd sisseln chf sapac corporation ltd chempharm aremarked either single dot teranol ltd lalden chf roche pharma limited cad chileproductos roche ltda group interest switzerland ltd reinach roche diag santiago de chile mxn roche vitaminas double dot nostics schweiz ltd rotkreuz chf chile sa puerto varas usd china group interest roche diagnostics international ltd cham rocheshanghai fine chemicals ltd shanghai chf roche vitamins europe ltd birs usd roche china limited shanghai share capital shown millions local felden chf roche instrument center ltd usd shanghai roche pharmaceuticals currency rotkreuz chf roche consumer health limited shanghai usd roche shanghai share capital less local currency ltd kaiseraugst chf roche vitamins ltd vitamins ltd shanghai usd roche units basel chf imib institute medical zhongya wuxi citric acid ltd wuxi usd informatics biostatistics ltd basel chf roche diagnostics shanghai limited shanghai basilea pharmaceutica ltd basel chf usd roche hong kong limited hong includes changes group membership roche finanz ag basel chf roche kong hkd roche diagnostics hong february kapitalmarkt ag basel chf roche trea kong limited hong kong hkd sury management europe ltd basel chf colombiaproductos roche sa bogot roche vitamins holding ag basel chf cop roche vitaminas colombia sa roche holding ag basel chf valor bogot cop costa ricaroche servi fides ag chur chf syntex corporation cios sa san jos usd roche vitaminas basel chf rabbitair ltd zurichkloten costa rica sa san jos usd productos chf pharmexbio ltd zug chf roche sa san jos usd czech republic argentinaproductos roche sa qumica e roche sro prague czk denmark industrial buenos aires ars roche vita roche hvidovre dkk roche vitamins minas argentina sa buenos aires ars hvidovre dkk dominican republic australiaroche products pty limited dee productos rochedominicana sa santo aud roche vitamins australia pty domingo dop roche vitaminas domini limited french forest aud syntex aus cana sa santo domingo dop ecuador tralia limited north sydney aud roche roche ecuador sa quito usd roche diagnostics australia pty limited castle hill vitaminas ecuador sa quito usd egypt aud austriaroche austria gmbh rovigypt ltd giza egp roche egypt vienna eur roche diagnostics gmbh ltd giza egp el salvadorproductos vienna eur bangladeshroche roche elsalvador sa san salvador usd bangladesh ltd dhaka bdt belgiumnv finlandroche oy espoo eur france roche sa brussels eur sacitrique hoffmannlaroche france sas neuillysur belge nv tienen eur roche vitamins seine eur roche sa neuillysurseine nv deinzeastene eur rochediag eur roche diagnostics sa meylan nostics belgium sa brussels eur eur roche vitamines france sa bermudacorange ltd hamilton usd villageneuf eur laboratoires roche roche capital transactions limited hamilton nicholas sa gaillard eur germany usd roche financial products limited roche deutschland holding gmbh grenzach hamilton usd roche international wyhlen dem corange deutschland finance bermuda ltd hamilton usd holding gmbh mannheim eur consulab roche international ltd hamilton usd mannheim gmbh mannheim eur canadian pharmholding ltd hamilton pharma waldhof gmbh co kg mannheim usd corange international ltd hamilton eur hoffmannla roche aktienge usd roche capital management ltd hamilton sellschaft grenzachwyhlen eur roche usd roche intertrade ltd hamilton consumer health deutschland gmbh eppstein usd syntex pharmaceuticals eur roche diagnostics gmbh mannheim international ltd hamilton usd roche eur galenus mannheim gmbh healthcare limited hamilton usd brazil mannheim eur hestia health care produtos roche qumicos e farmacuticos sa gmbh mannheim eur roche vitamine paulo brl roche diagnostics brasil gmbh grenzachwyhlen eur great ltda paulo brl roche vitaminas britainroche products limited welwyn garden brasil ltda paulo brl canada city gbp roche diagnostics ltd lewes hoffmannlaroche limited toronto cad gbp roche vitamins uk ltd welwyn subsidiaries associated companiesgarden city gbp roche registration new zealand pty ltd auckland nzd ticaret istanbul trl roche limited welwyn garden city gbp roche nicaraguaproductos roche nicaragua sa vitaminleri limited sirketi istanbul holding uk limited welwyn garden city managua nio norwayroche norge trl uruguayroche international ltd uruguay gbp antisoma plc london greeceroche oslo nok pakistanroche pakistan ltd montevideo sapac corporation ltd uruguay hellas sa athens eur roche vita karachi pkr panamaproductos roche montevideo roche vitaminas uruguay sa mins hellas epe athens eur roche interamericana sa panama city usd montevideo uyp usaroche holdings vitamins international marketing centre epe productos roche panam sa panama city inc wilmington delaware usd athens eur guatemalaproductos roche pab roche vitaminas interamrica sa panama hoffmannlaroche inc nutley new jersey guatemala sa guatemala gtq roche city usd roche capital corporation usd roche laboratories inc nutley vitaminas guatemala sa guatemala gtq panama city roche financial management newjersey roche vitamins inc guernsey roche capital market international inc panama city chf syntex corporation parsippany new jersey usd roche limited stpeter port chf roche inter panama city usd peruproductos roche molecular systems inc pleasanton california national finance corporation limited st peter qumica farmacutica sa lima pen american roche international inc little falls port chf roche financial market limited roche vitaminas per sa lima pen new jersey cad roche carolina inc st peter port guernsey chfhonduraspro philippinesroche philippines inc makati florence southcarolina genentech inc ductos roche honduras sa tegucigalpa php roche vitamins philippines inc south san francisco california usd hnl roche vitaminas centroamricana caribe manila php polandroche polska roche palo alto llc palo alto california sa puerto corts hnl hungaryroche spzoo warsaw pln roche diagnostics usd roche colorado corporation boulder hungary ltd budapest huf roche vita polska sp z oo warsaw pln roche colorado usd bayerroche llc mins hungary ltd ujhartyan huf india witaminy polska sp zoo mszczonw morristown new jersey usd roche roche scientific company india private limited pln portugalroche farmacutica qumica lda diagnostics corporation indianapolis indiana mumbai inr roche diagnostics india amadora eur roche sistemas de diag usd venezuelaproductos roche sa pvtltd mumbai inr indonesiapt roche nsticos sociedade unipessoal lda lindaa caracas veb roche vitaminas indonesia jakarta idr irelandroche velha eur puerto ricosyntex puerto venezuela sa lavictoria vebvietnam products ireland limited dublin eur rico inc humacao usd russiaroche roche vitamins vietnam limited binhduong roche ireland limited clarecastle eur moscow ltd moscow rub singapore province usd israelroche pharmaceuticals israel ltd tel roche singapore pte ltd singapore sgd aviv italyroche spa milan eur roche diagnostics asia pacific pte ltd singa roche diagnostics spa milan eur pore sgd roche vitamins asia pacific istituto delle vitamine spa milan eur pte ltd singapore sgd boehringer japan chugai pharmaceuticals co ltd tokyo mannheim far east pte ltd singapore jpy nutritec co ltd tokyo sgd south africaroche products proprietary jpy roche diagnostics kk tokyo limited johannesburg zar roche vita jpy roche vitamins japan kk tokyo mins south africa pty limited johannesburg jpy malaysiaroche malaysia sdn bhd zar south korearoche korea company kuala lumpur myr roche diagnostics ltd seoul krw roche diagnostics malaysia sdn bhd kuala lumpur myr korea co ltd seoul krw roche roche vitamins malaysia sdn bhd kuala vitamins korea ltd seoul krw lumpur myr mexicoproductos roche spainroche farma sa madrid eur sa de cv mexico city mxn syntex sa roche vitaminas sa madrid eur de cv mexico city mxn grupo roche andreu roche sa madrid eur syntex syntex de mxico sa de cv mexico city roche sa madrid eur roche diagnos mxn lakeside de mxico sa de cv mexico tics sl barcelona eur boehringer city mxn roche vitaminas mxico sa mannheim roche sa madrid eur swe de cv el salto jalisco mxn morocco denroche ab stockholm sek roche roche sa casablanca mad roche diagnostics scandinavia ab bromma sek immobilire maroc sarl casablanca taiwanroche products ltd taipei twd mad thenetherlandsroche pharmholding bv roche diagnostics ltd taipei twd mijdrecht eur roche nederland bv roche vitamins taiwan limited taipei mijdrecht eur roche diagnostics twd thailandroche thailand limited bangkok nederland bv almere eur roche vita thb rovithai limited bangkok mins bv venlo eur new zealandroche thb roche diagnostics thailand limited products new zealand limited auckland bangkok thb turkeyroche ms nzd roche vitamins new zealand lim tahzarlari sanayi anonim sirketi istanbul ited auckland nzd roche diagnostics trl roche diagnostik sistemleri subsidiaries associated companies cautionary statement regarding forwardlooking statements annual report contains certain forward opments economic conditions delay looking statements forwardlooking inability obtaining regulatory approvals bring statements may identified bywords ing products market fluctuations currency believes expects anticipates projects intends exchange rates general financial market seeks estimates future similar conditions uncertainties discovery devel expressions discussion among opment marketing new products new uses things strategy goals plans intentions various existing products increased government factors may cause actual results differ materially pricing pressures interruptions production future reflected forwardlook loss inability obtain adequate protection ing statements contained annual report intellectual property rights litigation among others pricing product initiatives loss key executives orother employees ofcompetitors legislative regulatory devel adverse publicity news coverage published f hoffmannla roche ltd basel switzerland tel fax media office corporate communications basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publications email baselwebmasterrochecom next annual general meeting april trademarks mentioned enjoy legal protection roche annual report published german original language english roche annual report issued f hoffmannla roche ltd basel corporate communications design wirz identity ag zurich photos mike frei zurich roche corporate photolibrary basel typesetting staufferfebel ag basel lithos lithoteam ag allschwilbasel printers birkhusergbc ag reinachbasel binding buchbinderei grollimund ag reinachbasel cover vascular diseases crystals neprilysin human neutral endopeptidasediagnostics sales division pharmaceuticals asia latin america sales region europe north america others others diagnostics employees division pharmaceuticals latin america asia north america employees region others europe adjusted basis